

Phase III Trial of Standard-Dose Intravenous Cisplatin
High-Dose Carboplatin Followed by Intravenous Paclitaxel
Small-Volume Stage III Ovarian Carcinoma: An Intergroup
Oncology Group, Southwestern Oncology Group, and Eastern
Group

Journal of Clinical Oncology

19, 1001-1007

DOI: [10.1200/jco.2001.19.4.1001](https://doi.org/10.1200/jco.2001.19.4.1001)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Intraperitoneal Drug Delivery of Antineoplastics. <i>Drugs</i> , 2001, 61, 1057-1065.	4.9	49
2	Pursuit of Optimum Outcomes in Ovarian Cancer. <i>Drugs</i> , 2001, 61, 1103-1120.	4.9	8
3	Treatment of platinum-resistant ovarian cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2001, 2, 1299-1306.	0.9	12
4	Intraperitoneal Therapy for Ovarian Cancer: A Sacrifice Bunt. <i>Journal of Clinical Oncology</i> , 2001, 19, 921-923.	0.8	16
5	Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2- β -deoxyuridine and leucovorin. <i>Anti-Cancer Drugs</i> , 2001, 12, 505-511.	0.7	3
6	Intraperitoneal chemotherapy is appropriate first line therapy for patients with optimally debulked ovarian cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 38, 171-175.	2.0	16
7	Second-Line Therapy for Potentially Platinum-Sensitive Recurrent Ovarian Cancer: What Is Optimal Treatment?. <i>Gynecologic Oncology</i> , 2001, 81, 1-2.	0.6	10
8	Improved Therapeutic Index of Lower Dose Topotecan Chemotherapy in Recurrent Ovarian Cancer. <i>Gynecologic Oncology</i> , 2001, 83, 257-262.	0.6	54
9	Intraperitoneal chemotherapy in the management of malignant disease. <i>Expert Review of Anticancer Therapy</i> , 2001, 1, 142-148.	1.1	44
10	Phase I and pharmacologic study of i.p. 9-aminocamptothecin given as six fractions over 14 days. <i>Anti-Cancer Drugs</i> , 2002, 13, 819-825.	0.7	8
11	Chemotherapy Options for Patients with Relapsed Epithelial Ovarian Cancer. <i>American Journal of Cancer</i> , 2002, 1, 205-216.	0.4	0
12	Part I: Chemotherapy for epithelial ovarian cancer—treatment at first diagnosis. <i>Lancet Oncology</i> , The, 2002, 3, 529-536.	5.1	134
14	Neue Aspekte in der gynäkologischen Onkologie. <i>Gynäkologisch-geburtshilfliche Rundschau</i> , 2002, 42, 175-177.	0.9	0
15	Intraperitoneal Therapy for Stage III Ovarian Cancer: A Therapy Whose Time Has Come!. <i>Journal of Clinical Oncology</i> , 2002, 20, 3944-3946.	0.8	68
16	Future directions in the treatment of ovarian cancer. <i>Seminars in Oncology</i> , 2002, 29, 32-42.	0.8	50
17	Chemotherapy for advanced epithelial ovarian carcinoma. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2002, 16, 553-571.	1.4	16
18	Combination chemotherapy with paclitaxel and intraperitoneal cisplatin for ovarian cancer with disseminated lesions in the peritoneum and the diaphragm. <i>International Journal of Clinical Oncology</i> , 2002, 7, 356-360.	1.0	3
19	Primäre Chemotherapie beim fortgeschrittenen Ovarialkarzinom. <i>Onkologie</i> , 2002, 8, 1171-1177.	0.7	0

#	ARTICLE	IF	CITATIONS
20	First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. <i>British Journal of Cancer</i> , 2002, 87, 815-824.	2.9	112
21	Systematic Review of First-Line Chemotherapy for Newly Diagnosed Postoperative Patients with Stage II, III, or IV Epithelial Ovarian Cancer. <i>Gynecologic Oncology</i> , 2002, 85, 71-80.	0.6	133
22	Second-Line Therapy of Ovarian Cancer with Paclitaxel Administered by Both the Intravenous and Intraperitoneal Routes: Rationale and Case Reports. <i>Gynecologic Oncology</i> , 2002, 86, 95-98.	0.6	5
23	Curative and palliative aspects of regional chemotherapy in combination with surgery. <i>Supportive Care in Cancer</i> , 2003, 11, 1-10.	1.0	24
24	Intraperitoneal chemotherapy for ovarian cancer. <i>Current Oncology Reports</i> , 2003, 5, 447-453.	1.8	5
25	Phase I/II clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato(trans-R, R-1). <i>Journal of Clinical Research and Clinical Oncology</i> , 2003, 129, 549-555.	1.2	26
26	Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: a Southwest Oncology Group trial. <i>Gynecologic Oncology</i> , 2003, 88, 282-288.	0.6	11
27	Prevention of chemotherapy-induced intraperitoneal adhesion formation in rats by icodextrin at a range of concentrations. <i>Gynecologic Oncology</i> , 2003, 88, 304-308.	0.6	11
28	First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up. <i>Gynecologic Oncology</i> , 2003, 90, 637-643.	0.6	86
29	First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2003, 90, S8-S15.	0.6	68
30	Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission. <i>Gynecologic Oncology</i> , 2003, 91, 341-345.	0.6	38
31	Carboplatin plus paclitaxel combination chemotherapy: impact of sequence of drug administration on treatment-induced neutropenia. <i>Gynecologic Oncology</i> , 2003, 91, 118-122.	0.6	8
32	Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2003, 13, 196-203.	1.2	105
33	Optimizing primary chemotherapy in ovarian cancer. <i>Hematology/Oncology Clinics of North America</i> , 2003, 17, 957-968.	0.9	28
34	Intraperitoneal therapy as consolidation for patients with ovarian cancer and negative reassessment after platinum-based chemotherapy. <i>Hematology/Oncology Clinics of North America</i> , 2003, 17, 969-975.	0.9	5
35	Progress in ovarian cancer. <i>European Journal of Cancer, Supplement</i> , 2003, 1, 43-55.	2.2	7
36	What are the clinical trial priorities of the future?. <i>European Journal of Cancer, Supplement</i> , 2003, 1, 147-154.	2.2	0
37	Intraperitoneal chemotherapy for ovarian cancer: a question of feasibility?. <i>Drug Resistance Updates</i> , 2003, 6, 165-167.	6.5	5

#	ARTICLE	IF	CITATIONS
38	Intraperitoneal antineoplastic drug delivery: rationale and results. <i>Lancet Oncology</i> , The, 2003, 4, 277-283.	5.1	208
39	Developmental Chemotherapy and Management of Recurrent Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 149s-167.	0.8	59
40	Regarding "Sweet Time Unafflicted". <i>Journal of Clinical Oncology</i> , 2003, 21, 958-958.	0.8	1
41	Combined Intraperitoneal and Intravenous Chemotherapy for Women With Optimally Debulked Ovarian Cancer: Results From an Intergroup Phase II Trial. <i>Journal of Clinical Oncology</i> , 2003, 21, 1313-1319.	0.8	55
43	Current Therapies in Ovarian Cancer. <i>Cancer Investigation</i> , 2003, 21, 148-156.	0.6	23
44	Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies. <i>British Journal of Cancer</i> , 2003, 89, S23-S28.	2.9	116
45	Carboplatin Equals Cisplatin: But How Do I Prescribe It?. <i>Journal of Clinical Oncology</i> , 2003, 21, 3183-3185.	0.8	14
46	Intraperitoneal Chemotherapy for Stage III Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 957-957.	0.8	4
47	Maybe More Is Better. <i>Journal of Clinical Oncology</i> , 2003, 21, 2454-2456.	0.8	10
48	Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer. <i>Anti-Cancer Drugs</i> , 2003, 14, 103-110.	0.7	44
49	Escalating doses of paclitaxel and epirubicin in combination with cisplatin in advanced ovarian epithelial carcinoma: a phase II study. <i>Anti-Cancer Drugs</i> , 2003, 14, 359-364.	0.7	6
50	Ovarian and Fallopian Tube Cancers. , 0, , 377-393.		3
51	Intraperitoneal Chemotherapy. , 2003, , 505-513.		1
52	Counterpoint: Intraperitoneal Chemotherapy: An Investigational Treatment in Ovarian Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2004, 2, 555-560.	2.3	2
53	Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group. <i>International Journal of Gynecological Cancer</i> , 2004, 14, 224-228.	1.2	3
54	Medical treatment of epithelial ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2004, 4, 1125-1143.	1.1	5
55	Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma. <i>New England Journal of Medicine</i> , 2004, 351, 2489-2497.	13.9	366
56	Update on Gynecologic Oncology Group (GOG) Trials in Ovarian Cancer. <i>Cancer Investigation</i> , 2004, 22, 11-20.	0.6	16

#	ARTICLE	IF	CITATIONS
57	First-Line Therapy for Ovarian Carcinoma: What's Next?. <i>Cancer Investigation</i> , 2004, 22, 21-28.	0.6	25
58	Intraperitoneal Cisplatin with Intraperitoneal Gemcitabine in Patients with Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 2962-2967.	3.2	41
59	Fatigue in cancer patients receiving chemotherapy: an analysis of published studies. <i>Annals of Oncology</i> , 2004, 15, 712-720.	0.6	98
60	Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group. <i>International Journal of Gynecological Cancer</i> , 2004, 14, 224-228.	1.2	23
61	Remaining controversies in the upfront management of advanced ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2004, 14, 707-720.	1.2	18
62	Relevance of chemotherapy dose and schedule to outcomes in ovarian cancer. <i>Seminars in Oncology</i> , 2004, 31, 19-24.	0.8	25
63	Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study. <i>Gynecologic Oncology</i> , 2004, 94, 98-106.	0.6	15
64	Brain metastases of epithelial ovarian carcinoma responding to cisplatin and gemcitabine combination chemotherapy: a case report and review of the literature. <i>Gynecologic Oncology</i> , 2004, 94, 267-276.	0.6	33
65	Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. <i>American Journal of Obstetrics and Gynecology</i> , 2004, 190, 910-923.	0.7	80
66	Cytoreductive Surgery and Intraperitoneal Chemohyperthermia for Recurrent Peritoneal Carcinomatosis from Ovarian Cancer. <i>World Journal of Surgery</i> , 2004, 28, 1040-1045.	0.8	111
67	Cancer of the Ovary. <i>New England Journal of Medicine</i> , 2004, 351, 2519-2529.	13.9	1,713
69	First-Line Chemotherapy for the Treatment of Epithelial Ovarian Cancer. <i>Postgraduate Obstetrics & Gynecology</i> , 2004, 24, 1-5.	0.1	0
70	Comprehensive approach to advanced primary and recurrent ovarian cancer: a personal experience. <i>Expert Review of Anticancer Therapy</i> , 2004, 4, 477-487.	1.1	7
71	Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein binding. <i>Anti-Cancer Drugs</i> , 2005, 16, 1009-1016.	0.7	39
72	Intraperitoneal chemotherapy in ovarian cancer: who and when?. <i>Current Opinion in Obstetrics and Gynecology</i> , 2005, 17, 83-86.	0.9	7
73	Current management of ovarian carcinoma. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 275-286.	0.2	0
74	Intraoperative radiation therapy in recurrent ovarian cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 1114-1121.	0.4	30
75	Epithelial Ovarian Cancer: A Review of Current Management. <i>Clinical Oncology</i> , 2005, 17, 399-411.	0.6	83

#	ARTICLE	IF	CITATIONS
76	Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: A review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 55, 153-166.	2.0	53
77	New agents for the treatment of ovarian cancer: the next generation. <i>International Journal of Gynecological Cancer</i> , 2005, 15, 252-257.	1.2	9
78	Standard treatment in advanced ovarian cancer in 2005: the state of the art. <i>International Journal of Gynecological Cancer</i> , 2005, 15, 212-220.	1.2	59
79	Ovarian cancer: is the news good enough?. <i>International Journal of Gynecological Cancer</i> , 2005, 15, 298-306.	1.2	17
80	Intraperitoneal hyperthermic chemotherapy in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2005, 15, 233-239.	1.2	58
81	Preliminary toxicity analysis of intraperitoneal carboplatin in combination with intravenous paclitaxel chemotherapy for patients with carcinoma of the ovary, peritoneum, or fallopian tube. <i>International Journal of Gynecological Cancer</i> , 2005, 15, 426-431.	1.2	34
82	Future options for first-line therapy of advanced ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2005, 15, 42-50.	1.2	44
83	High-dose chemotherapy with autologous haemopoietic support for advanced ovarian cancer in first complete remission: retrospective analysis from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2005, 36, 25-31.	1.3	13
85	Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2005, 97, 10-15.	0.6	70
86	Feasibility of laparoscopic peritonectomy followed by intra-peritoneal chemohyperthermia: An experimental study. <i>Gynecologic Oncology</i> , 2005, 99, 358-361.	0.6	41
87	Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin—A Sankai Gynecology Study Group (SGSG) study. <i>Gynecologic Oncology</i> , 2005, 99, 591-596.	0.6	77
88	A modified technique for insertion of intraperitoneal port for chemotherapy. <i>Journal of Surgical Oncology</i> , 2005, 90, 247-248.	0.8	5
90	Consolidation therapy for ovarian cancer. <i>Women's Oncology Review</i> , 2005, 5, 3-8.	0.0	0
91	Intraperitoneal hyperthermic chemotherapy in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2005, 15, 233-239.	1.2	80
92	Quality-of-Life Comparisons in a Randomized Trial of Interval Secondary Cytoreduction in Advanced Ovarian Carcinoma: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 5605-5612.	0.8	109
93	Gene Expression Profiles Predict Early Relapse in Ovarian Cancer after Platinum-Paclitaxel Chemotherapy. <i>Clinical Cancer Research</i> , 2005, 11, 2149-2155.	3.2	139
94	Intraperitoneal chemotherapy for epithelial ovarian carcinoma. <i>Future Oncology</i> , 2005, 1, 289-292.	1.1	0
95	Targeted therapy for epithelial ovarian cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2005, 9, 501-513.	1.5	6

#	ARTICLE	IF	CITATIONS
96	Expression and Targeting of Interleukin-4 Receptor for Primary and Advanced Ovarian Cancer Therapy. <i>Cancer Research</i> , 2005, 65, 8388-8396.	0.4	27
97	Patterns of Gene Expression That Characterize Long-term Survival in Advanced Stage Serous Ovarian Cancers. <i>Clinical Cancer Research</i> , 2005, 11, 3686-3696.	3.2	246
98	Clinical trials in ovarian carcinoma: study methodology. <i>Annals of Oncology</i> , 2005, 16, viii20-viii29.	0.6	18
99	Role of chemotherapy in the management of epithelial ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 139-147.	1.1	7
100	Investigational agents for epithelial ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 855-868.	1.1	7
101	Emerging drugs for ovarian cancer. <i>Expert Opinion on Emerging Drugs</i> , 2005, 10, 413-424.	1.0	39
102	Toxicity of intraperitoneal chemotherapy may be related to age in women treated for optimally debulked ovarian cancer. <i>Community Oncology</i> , 2005, 2, 271-275.	0.2	5
104	A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer. <i>European Journal of Cancer</i> , 2005, 41, 539-548.	1.3	14
105	Front-Line Treatment of Epithelial Ovarian Cancer. <i>American Journal of Cancer</i> , 2005, 4, 221-231.	0.4	1
107	Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2006, 354, 34-43.	13.9	2,429
108	Staging, cytoreduction and chemotherapy improve long-term outcomes in patients with ovarian cancer. <i>Drugs and Therapy Perspectives</i> , 2006, 22, 10-13.	0.3	0
109	Intra-peritoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma. <i>International Journal of Hyperthermia</i> , 2006, 22, 161-172.	1.1	17
110	Intravenous chemotherapy with carboplatin/paclitaxel is the standard of care for patients with optimally resected stage III ovarian cancer. <i>Community Oncology</i> , 2006, 3, 350-351.	0.2	0
111	Intraperitoneal chemotherapy as primary treatment of advanced ovarian cancer. <i>Community Oncology</i> , 2006, 3, 352-353.	0.2	1
112	Weekly induction intraperitoneal chemotherapy after primary surgical cytoreduction in patients with advanced epithelial ovarian cancer. <i>World Journal of Surgical Oncology</i> , 2006, 4, 4.	0.8	3
113	Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: From laboratory bench to bedside. <i>Cancer Treatment Reviews</i> , 2006, 32, 471-482.	3.4	71
114	Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: Clinical considerations. <i>European Journal of Cancer</i> , 2006, 42, 2296-2302.	1.3	59
115	Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination. <i>European Journal of Surgical Oncology</i> , 2006, 32, 666-670.	0.5	48

#	ARTICLE	IF	CITATIONS
116	Novel therapeutic agents in ovarian cancer. <i>European Journal of Surgical Oncology</i> , 2006, 32, 875-886.	0.5	53
117	Medical Treatment of Ovarian Carcinoma. , 0, , 82-93.		1
119	Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. , 2006, , CDO05340.		85
120	Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis. <i>Anti-Cancer Drugs</i> , 2006, 17, 1211-1217.	0.7	18
121	Intraperitoneal chemotherapy for ovarian cancer. <i>Current Opinion in Oncology</i> , 2006, 18, 507-515.	1.1	14
122	Gene expression patterns of chemoresistant and chemosensitive serous epithelial ovarian tumors with possible predictive value in response to initial chemotherapy. <i>International Journal of Oncology</i> , 2006, 29, 919.	1.4	9
123	Diagnosis and Management of Epithelial Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2006, 107, 1399-1410.	1.2	176
124	Intraperitoneal Chemotherapy for Epithelial Ovarian Cancer. <i>Obstetrical and Gynecological Survey</i> , 2006, 61, 529-534.	0.2	1
125	Intraperitoneal Chemotherapy for Ovarian Cancer: Where Are We Now?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006, 4, 941-946.	2.3	10
126	Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: Molecular signatures of chemoresistant tumors. <i>International Journal of Oncology</i> , 2006, 29, 5.	1.4	39
127	Ovarian cancer-can intraperitoneal therapy be regarded as new standard in Germany?. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 1756-1760.	1.2	11
128	Intraperitoneal chemotherapy for advanced epithelial ovarian cancer: a Canadian perspective. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 1761-1765.	1.2	4
129	Phase I/II trial of multicycle high-dose chemotherapy with peripheral blood stem cell support for treatment of advanced ovarian cancer. <i>Bone Marrow Transplantation</i> , 2006, 38, 493-499.	1.3	15
130	The rapid uptake of concurrent chemotherapy for cervix cancer patients treated with curative radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 1389-1394.	0.4	23
132	Mathematical modeling of ovarian cancer treatments: Sequencing of surgery and chemotherapy. <i>Journal of Theoretical Biology</i> , 2006, 242, 62-68.	0.8	34
133	Surgical management of peritoneal carcinomatosis: from clinical research to standard of care. <i>Clinical and Translational Oncology</i> , 2006, 8, 545-546.	1.2	2
134	Intraperitoneal chemotherapy for frontline ovarian cancer therapy: Vindicated or vilified?. <i>Current Oncology Reports</i> , 2006, 8, 439-440.	1.8	0
135	Historical progress in the initial management of ovarian cancer: Intraperitoneal chemotherapy. <i>Current Oncology Reports</i> , 2006, 8, 455-464.	1.8	1

#	ARTICLE	IF	CITATIONS
136	Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study. <i>Gynecologic Oncology</i> , 2006, 100, 133-138.	0.6	59
137	Sequential gemcitabine+carboplatin followed by paclitaxel+carboplatin in the first-line treatment of advanced ovarian cancer: A phase II study. <i>Gynecologic Oncology</i> , 2006, 101, 114-119.	0.6	4
138	Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2006, 100, 27-32.	0.6	295
139	Identification of prognostic factors after positive second-look surgery in epithelial ovarian carcinoma. <i>Gynecologic Oncology</i> , 2006, 102, 8-14.	0.6	7
140	The role of maintenance therapy and novel taxanes in ovarian cancer. <i>Gynecologic Oncology</i> , 2006, 102, 218-225.	0.6	22
141	Intraperitoneal chemotherapy for women with advanced epithelial ovarian carcinoma. <i>Gynecologic Oncology</i> , 2006, 100, 3-4.	0.6	47
142	Maspin expression in epithelial ovarian cancer and associations with poor prognosis: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2006, 101, 390-397.	0.6	30
143	Intraperitoneal chemotherapy in patients with nodal metastasis. <i>Gynecologic Oncology</i> , 2006, 102, 130.	0.6	1
144	Icodextrin enhances survival in an intraperitoneal ovarian cancer murine model utilizing gene therapy. <i>Gynecologic Oncology</i> , 2006, 103, 985-989.	0.6	3
145	Intraperitoneal cisplatin therapy in ovarian cancer: Comparison with standard intravenous carboplatin and paclitaxel. <i>Gynecologic Oncology</i> , 2006, 103, 1-6.	0.6	55
146	The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages III-IV epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2006, 103, 1083-1090.	0.6	305
147	Optimal cytoreduction for advanced epithelial ovarian cancer: A commentary. <i>Gynecologic Oncology</i> , 2006, 103, 329-335.	0.6	105
148	More on intraperitoneal therapy. <i>Gynecologic Oncology</i> , 2006, 103, 763.	0.6	1
149	Re: Neoadjuvant chemotherapy followed by vaginal radical trachelectomy in bulky stage IB1 cervical cancer. <i>Gynecologic Oncology</i> , 2006, 103, 763-764.	0.6	3
151	Systemic Therapy for Ovarian Cancer: Current Status and New Treatments. <i>Seminars in Oncology</i> , 2006, 33, 3-11.	0.8	174
152	Unresolved Issues in the Chemotherapeutic Management of Gynecologic Malignancies. <i>Seminars in Oncology</i> , 2006, 33, 33-38.	0.8	7
153	Clinical Efficacy Supporting the Role of Intraperitoneal Drug Delivery in the Primary Chemotherapeutic Management of Small-Volume Residual Advanced Ovarian Cancer. <i>Seminars in Oncology</i> , 2006, 33, 3-7.	0.8	83
154	Maximizing the Delivery of Intraperitoneal Therapy While Minimizing Drug Toxicity and Maintaining Quality of Life. <i>Seminars in Oncology</i> , 2006, 33, 8-17.	0.8	71

#	ARTICLE	IF	CITATIONS
156	New and Emerging Intraperitoneal (IP) Drugs for Ovarian Cancer Treatment. <i>Seminars in Oncology</i> , 2006, 33, 18-24.	0.8	15
157	Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients. <i>BMC Cancer</i> , 2006, 6, 183.	1.1	51
158	Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. <i>Journal of Surgical Oncology</i> , 2006, 94, 316-324.	0.8	110
159	Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. <i>Cancer Biology and Therapy</i> , 2006, 5, 1708-1713.	1.5	100
160	Clinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the Ovary. <i>Obstetrics and Gynecology</i> , 2006, 108, 361-368.	1.2	242
162	Should patients with ovarian cancer receive intraperitoneal chemotherapy following initial cytoreductive surgery?. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 416-417.	4.3	5
163	Case 11-2006. <i>New England Journal of Medicine</i> , 2006, 354, 1615-1625.	13.9	4
164	Intraperitoneal Chemotherapy Comes of Age. <i>New England Journal of Medicine</i> , 2006, 354, 77-79.	13.9	63
165	Intraperitoneal Chemotherapy in Ovarian Cancer Remains Experimental. <i>Journal of Clinical Oncology</i> , 2006, 24, 4528-4530.	0.8	83
166	Challenges for chemotherapy in ovarian cancer. <i>Annals of Oncology</i> , 2006, 17, v181-v187.	0.6	95
167	Molecular Targets of Ovarian Carcinomas with Acquired Resistance to Platinum/Taxane Chemotherapy. <i>Current Cancer Drug Targets</i> , 2006, 6, 207-227.	0.8	12
168	Ovarian cancer: a focus on management of recurrent disease. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 604-611.	4.3	96
169	Intraperitoneal chemotherapy in advanced ovarian cancer: recognition at last. <i>Annals of Oncology</i> , 2006, 17, x241-x246.	0.6	9
170	Intraperitoneal Chemotherapy of Ovarian Cancer: A Review, With a Focus on Practical Aspects of Treatment. <i>Journal of Clinical Oncology</i> , 2006, 24, 988-994.	0.8	171
171	Multi-Institutional Reciprocal Validation Study of Computed Tomography Predictors of Suboptimal Primary Cytoreduction in Patients With Advanced Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 384-389.	0.8	224
172	Phase I Trial of Intraperitoneal Gemcitabine in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity. <i>Clinical Cancer Research</i> , 2007, 13, 1232-1237.	3.2	35
173	Extraperitoneal Leakage as a Possible Explanation for Failure of One-Time Intraperitoneal Treatment in Ovarian Cancer. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2007, 22, 508-514.	0.7	6
174	Intraperitoneal Chemotherapy for Ovarian Cancer: Overview and Perspective. <i>Journal of Clinical Oncology</i> , 2007, 25, 2867-2872.	0.8	31

#	ARTICLE	IF	CITATIONS
175	Evidence-Based Research for Intraperitoneal Chemotherapy in Epithelial Ovarian Cancer. <i>Clinical Journal of Oncology Nursing</i> , 2007, 11, 211-216.	0.3	7
176	Intraperitoneal Chemotherapy: Implications Beyond Ovarian Cancer. <i>Clinical Journal of Oncology Nursing</i> , 2007, 11, 881-889.	0.3	8
177	Intraperitoneal Chemotherapy of Ovarian Cancer. <i>Women's Health</i> , 2007, 3, 433-440.	0.7	0
179	Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer. <i>Annals of Oncology</i> , 2007, 18, 1943-1950.	0.6	110
180	Health-Related Quality of Life During and After Intraperitoneal Versus Intravenous Chemotherapy for Optimally Debulked Ovarian Cancer: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 437-443.	0.8	187
181	A Gynecologic Oncology Group Study of Platinum-DNA Adducts and Excision Repair Cross-Complementation Group 1 Expression in Optimal, Stage III Epithelial Ovarian Cancer Treated with Platinum-Taxane Chemotherapy. <i>Cancer Research</i> , 2007, 67, 4474-4481.	0.4	38
182	Experience With Bevacizumab in the Management of Epithelial Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 2902-2908.	0.8	107
183	Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. <i>International Journal of Hyperthermia</i> , 2007, 23, 431-442.	1.1	103
184	New, Expanded, and Modified Use of Approved Antineoplastic Agents in Ovarian Cancer. <i>Oncologist</i> , 2007, 12, 186-190.	1.9	22
185	Phase III Trial of High-Dose Sequential Chemotherapy With Peripheral Blood Stem Cell Support Compared With Standard Dose Chemotherapy for First-Line Treatment of Advanced Ovarian Cancer: Intergroup Trial of the AGO-Ovar/AIO and EBMT. <i>Journal of Clinical Oncology</i> , 2007, 25, 4187-4193.	0.8	75
186	Current and Future Directions of Clinical Trials for Ovarian Cancer. <i>Cancer Control</i> , 2007, 14, 44-51.	0.7	0
187	Ambivalency at the bedside: intraperitoneal chemotherapy. <i>Current Opinion in Obstetrics and Gynecology</i> , 2007, 19, 1-2.	0.9	1
188	Current Management Strategies for Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , 2007, 82, 751-770.	1.4	127
190	Improving outcome in the first-line management of advanced ovarian cancer. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 23-28.	2.2	3
191	GYNECOLOGICAL CANCERS. <i>Cancer Investigation</i> , 2007, 25, 24-31.	0.6	1
192	“Of Models and Men (or Women)” A Brief Story of a Mathematical Model and Its Influence on the Management of Ovarian Cancer. <i>Cancer Investigation</i> , 2007, 25, 666-667.	0.6	0
193	Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 3621-3627.	0.8	767
194	Current Management Strategies for Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , 2007, 82, 751-770.	1.4	156

#	ARTICLE	IF	CITATIONS
195	Cytoreductive Surgery for Gynecologic Malignancies—New Standards of Care. <i>Surgical Oncology Clinics of North America</i> , 2007, 16, 667-682.	0.6	7
196	Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival. <i>International Journal of Cancer</i> , 2007, 120, 2710-2714.	2.3	77
197	Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer. <i>Cancer</i> , 2007, 109, 692-702.	2.0	122
198	Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer. <i>Cancer</i> , 2007, 109, 645-649.	2.0	28
199	Intraperitoneal chemotherapy in the treatment of ovarian cancer. <i>Journal of Surgical Oncology</i> , 2007, 96, 541-542.	0.8	2
200	Trends in complementary/alternative medicine use by breast cancer survivors: Comparing survey data from 1998 and 2005. <i>BMC Women's Health</i> , 2007, 7, 4.	0.8	302
201	Cytoreduction and intraperitoneal heated chemotherapy for the treatment of endometrial carcinoma recurrent within the peritoneal cavity. <i>International Journal of Gynecological Cancer</i> , 2007, 17, 204-209.	1.2	23
202	A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2007, 17, 561-570.	1.2	82
203	Clinical trials in gynecological cancer. <i>International Journal of Gynecological Cancer</i> , 2007, 17, 547-556.	1.2	9
204	Principles and practice of intraperitoneal chemotherapy for ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2007, 17, 1-20.	1.2	81
206	Ototoxicity after intraperitoneal chemotherapy: a case report. <i>International Journal of Gynecological Cancer</i> , 2007, 17, 1133-1135.	1.2	4
207	Biodistribution of doxorubicin-alkylated poly(L-lysine citramide imide) conjugates in an experimental model of peritoneal carcinomatosis after intraperitoneal administration. <i>European Journal of Pharmaceutical Sciences</i> , 2007, 31, 43-52.	1.9	22
208	Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma†. <i>Gynecologic Oncology</i> , 2007, 105, 90-96.	0.6	83
209	Regulation of the metastasis suppressor gene MKK4 in ovarian cancer. <i>Gynecologic Oncology</i> , 2007, 105, 312-320.	0.6	21
210	Intraperitoneal chemotherapy for patients with advanced ovarian cancer: A review of the evidence and standards for the delivery of care. <i>Gynecologic Oncology</i> , 2007, 105, 747-756.	0.6	21
211	A relevant historical perspective on the current toxicity of IP chemotherapy: Implications for the future. <i>Gynecologic Oncology</i> , 2007, 105, 561-562.	0.6	1
212	Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. <i>Gynecologic Oncology</i> , 2007, 106, 193-200.	0.6	102
213	Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2007, 106, 221-232.	0.6	43

#	ARTICLE	IF	CITATIONS
214	Intraperitoneal hyperthermic chemotherapy using carboplatin: A phase I analysis in ovarian carcinoma. <i>Gynecologic Oncology</i> , 2007, 106, 207-210.	0.6	33
215	Response and outcomes in elderly patients with stages IIIc-IV ovarian cancer receiving platinum-taxane chemotherapy. <i>Gynecologic Oncology</i> , 2007, 106, 381-387.	0.6	75
216	The combination of chemotherapy and intraperitoneal MegaFas Ligand improves treatment of ovarian carcinoma. <i>Gynecologic Oncology</i> , 2007, 107, 14-21.	0.6	25
217	Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials. <i>Gynecologic Oncology</i> , 2007, 106, 279-281.	0.6	14
218	Current practice and new developments in ovarian cancer chemotherapy. <i>The Obstetrician and Gynaecologist</i> , 2007, 9, 265-269.	0.2	1
219	Effects of Carrier on Disposition and Antitumor Activity of Intraperitoneal Paclitaxel. <i>Pharmaceutical Research</i> , 2007, 24, 1691-1701.	1.7	121
221	Quality-of-Life Issues in the Management of Epithelial Ovarian Cancer. Current Treatment Options in <i>Oncology</i> , 2007, 8, 402-416.	1.3	13
222	Treatment guidelines in ovarian cancer. <i>Clinical and Translational Oncology</i> , 2007, 9, 308-316.	1.2	11
223	Intraperitoneal chemotherapy for optimally debulked advanced ovarian cancer: A new standard in patient care?. <i>Clinical and Translational Oncology</i> , 2007, 9, 409-411.	1.2	4
225	Treatment of peritoneal carcinomatosis from ovarian cancer. Present, future directions and proposals. <i>Clinical and Translational Oncology</i> , 2007, 9, 652-662.	1.2	23
226	Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer?. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 62, 137-147.	2.0	18
227	Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 61, 415-421.	1.1	22
229	Primary chemotherapy and maintenance therapy in epithelial ovarian cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2008, 1, 99-102.	0.3	1
230	Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. <i>Journal of Surgical Oncology</i> , 2008, 98, 283-290.	0.8	56
231	Treatment failure following complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from colorectal or appendiceal mucinous neoplasms. <i>Journal of Surgical Oncology</i> , 2008, 98, 295-299.	0.8	58
232	Prognostic factors for patients with stage IV epithelial ovarian cancer receiving intraperitoneal chemotherapy after second-look assessment. <i>Cancer</i> , 2008, 112, 2690-2697.	2.0	4
233	Cytoreductive Surgery and Intraoperative Hyperthermic Intraperitoneal Chemotherapy with Paclitaxel: A Clinical and Pharmacokinetic Study. <i>Annals of Surgical Oncology</i> , 2008, 15, 1183-1192.	0.7	65
234	Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival. <i>British Journal of Cancer</i> , 2008, 98, 1197-1203.	2.9	83

#	ARTICLE	IF	CITATIONS
235	National Cancer Instituteâ€œUnited States strategy regarding intraperitoneal chemotherapy for ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 26-28.	1.2	26
236	Strategies to examine new compounds for intraperitoneal use in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 33-35.	1.2	8
237	What is the optimal approach to the administration of intraperitoneal chemotherapy in ovarian cancer?. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 36-39.	1.2	6
238	Paclitaxel maintenance chemotherapy following intraperitoneal chemotherapy for ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 891-895.	1.2	11
239	Intraperitoneal chemotherapy in the management of patients with advanced epithelial ovarian cancer: a critical review of the literature. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 943-953.	1.2	25
240	Combination chemotherapy of intraperitoneal carboplatin and intravenous paclitaxel in suboptimally debulked epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 1210-1214.	1.2	16
241	The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. <i>Gynecologic Oncology</i> , 2008, 108, 287-292.	0.6	109
242	Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: A review of complications and completion rates. <i>Gynecologic Oncology</i> , 2008, 108, 342-347.	0.6	36
243	Critical thinking: An essential role in both the conduct and interpretation of gynecologic cancer clinical research. <i>Gynecologic Oncology</i> , 2008, 108, 462-465.	0.6	4
244	Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer. <i>Gynecologic Oncology</i> , 2008, 109, 39-42.	0.6	20
245	Evidence-based chemotherapy administration in advanced ovarian cancer: An impressive past, a disquieting present and an uncertain future. <i>Gynecologic Oncology</i> , 2008, 109, 4-7.	0.6	25
246	Progress in Gynecologic Cancer Research: The Gynecologic Oncology Group Experience. <i>Seminars in Oncology</i> , 2008, 35, 507-521.	0.8	19
247	Ovarian Cancer in Older Women. <i>Seminars in Oncology</i> , 2008, 35, 582-589.	0.8	21
248	Pharmaceutical Management of Ovarian Cancer. <i>Drugs</i> , 2008, 68, 771-789.	4.9	95
250	Intraperitoneal Chemotherapy for Stage III Ovarian Cancer Using the Gynecologic Oncology Group Protocol 172 Intraperitoneal Regimen: Effect of Supportive Care Using Aprepitant and Pegfilgrastim on Treatment Completion Rate. <i>Clinical Ovarian Cancer & Other Gynecologic Malignancies</i> , 2008, 1, 68-71.	0.2	4
251	A Comparison of Reimbursement for Outpatient Intraperitoneal Chemotherapy Versus Intravenous Therapy for Ovarian Cancer. <i>Clinical Ovarian Cancer & Other Gynecologic Malignancies</i> , 2008, 1, 75-77.	0.2	0
252	Intraperitoneal Chemotherapy: Practicality Versus Theory. <i>Clinical Ovarian Cancer & Other Gynecologic Malignancies</i> , 2008, 1, 72-74.	0.2	0
253	Highlights from: The Annual Meeting of the Society of Gynecologic Oncologists; March 9â€œ12, 2008; Tampa, FL. <i>Clinical Ovarian Cancer & Other Gynecologic Malignancies</i> , 2008, 1, 10-14.	0.2	1

#	ARTICLE	IF	CITATIONS
255	Targeted Cancer Therapy. , 2008, , .		11
256	Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies. Trends in Pharmacological Sciences, 2008, 29, 515-519.	4.0	47
257	Hyperthermia adds to chemotherapy. European Journal of Cancer, 2008, 44, 2546-2554.	1.3	457
258	A feasibility, pharmacokinetic and frequency-escalation trial of intraperitoneal chemotherapy in high risk gastrointestinal tract cancer. European Journal of Surgical Oncology, 2008, 34, 403-409.	0.5	4
259	Neoadjuvant chemotherapy prior to intraperitoneal chemotherapy in women with advanced ovarian cancer. Community Oncology, 2008, 5, 376-380.	0.2	1
260	Treatment of Xenografted Ovarian Carcinoma Using Paclitaxel-loaded Ultrasound Microbubbles. Academic Radiology, 2008, 15, 1574-1579.	1.3	22
261	â€œConflict-of-Interestâ€•and Participation in IRB Deliberations: An Alternative Perspective. Cancer Investigation, 2008, 26, 115-117.	0.6	1
262	Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer. Annals of Oncology, 2008, 19, 327-331.	0.6	54
263	Intraperitoneal Chemotherapy in Patients with Advanced Ovarian Cancer: The Con View. Oncologist, 2008, 13, 410-414.	1.9	23
264	Cost Effectiveness of Intraperitoneal Compared With Intravenous Chemotherapy for Women With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study. Journal of Clinical Oncology, 2008, 26, 4144-4150.	0.8	42
265	Office-Based Intraperitoneal Chemotherapy for Ovarian Cancer. Journal of Oncology Practice, 2008, 4, 225-228.	2.5	9
266	A Gene Signature Predicting for Survival in Suboptimally Debulked Patients with Ovarian Cancer. Cancer Research, 2008, 68, 5478-5486.	0.4	368
267	Relationship Between ERCC1 Polymorphisms, Disease Progression, and Survival in the Gynecologic Oncology Group Phase III Trial of Intraperitoneal Versus Intravenous Cisplatin and Paclitaxel for Stage III Epithelial Ovarian Cancer. Journal of Clinical Oncology, 2008, 26, 3598-3606.	0.8	67
268	Paclitaxel in the management of ovarian cancer. Expert Review of Obstetrics and Gynecology, 2008, 3, 287-299.	0.4	0
269	A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis. British Journal of Cancer, 2008, 98, 720-727.	2.9	8
270	Intraperitoneal chemotherapy: standard of care for patients with minimal residual stage III ovarian cancer?. Expert Review of Anticancer Therapy, 2008, 8, 1135-1147.	1.1	11
271	Ovarian cancer: front-line standard treatment in 2008. Annals of Oncology, 2008, 19, vii61-vii66.	0.6	12
272	Why i.p. therapy cannot yet be considered as a standard of care for the first-line treatment of ovarian cancer: a systematic review. Annals of Oncology, 2008, 19, 688-695.	0.6	22

#	ARTICLE	IF	CITATIONS
273	Intraperitoneal Chemotherapy for Women With Ovarian Cancer: Nursing Care and Considerations. <i>Clinical Journal of Oncology Nursing</i> , 2008, 12, 265-271.	0.3	5
274	Fatigue in Women Receiving Intraperitoneal Chemotherapy for Ovarian Cancer A Review of Contributing Factors. <i>Clinical Journal of Oncology Nursing</i> , 2008, 12, 445-454.	0.3	23
275	Tumor-Penetrating Microparticles for Intraperitoneal Therapy of Ovarian Cancer. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 327, 673-682.	1.3	86
276	Intraperitoneal Chemotherapy for Women with Epithelial Ovarian Cancer. <i>Oncologist</i> , 2008, 13, 403-409.	1.9	19
277	Ovarian, Cervical, and Endometrial Cancer. <i>Radiographics</i> , 2008, 28, 289-307.	1.4	7
278	Emerging drugs for ovarian cancer. <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 523-536.	1.0	9
279	Intraperitoneal Chemotherapy in Ovarian Cancer: An Update. <i>Cancer Journal (Sudbury, Mass)</i> , 2008, 14, 7-9.	1.0	4
280	Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin. <i>Therapeutics and Clinical Risk Management</i> , 2009, 5, 161.	0.9	16
284	Pegylated Liposomal Doxorubicin for Advanced Ovarian Cancer in Women who are Refractory to Both Platinum- and Paclitaxel-Based Chemotherapy Regimens. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2219.	0.1	1
285	Factors Related to Recurrence after Pathological Complete Response to Postoperative Chemotherapy in Patients with Epithelial Ovarian Cancer. <i>Tumori</i> , 2009, 95, 207-211.	0.6	5
286	A permutation test approach to phase II historical control trials. <i>Journal of Applied Statistics</i> , 2009, 36, 589-599.	0.6	1
287	Enhanced Delivery of Cisplatin to Intraperitoneal Ovarian Carcinomas Mediated by the Effects of Bortezomib on the Human Copper Transporter 1. <i>Clinical Cancer Research</i> , 2009, 15, 553-560.	3.2	70
288	The Role of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer. <i>Oncologist</i> , 2009, 14, 683-694.	1.9	77
289	Chemotherapy Resistance as a Predictor of Progression-Free Survival in Ovarian Cancer Patients Treated with Neoadjuvant Chemotherapy and Surgical Cytoreduction Followed by Intraperitoneal Chemotherapy: A Southwest Oncology Group Study. <i>Oncology</i> , 2009, 77, 395-399.	0.9	11
290	Targeting locoregional peritoneal dissemination in ovarian cancer. <i>Expert Review of Obstetrics and Gynecology</i> , 2009, 4, 133-147.	0.4	7
292	Anal Fissures Associated With Targeted Therapies in Ovarian Cancer. <i>Clinical Journal of Oncology Nursing</i> , 2009, 13, 638-642.	0.3	0
293	Platinum compounds 30 years after the introduction of cisplatin: Implications for the treatment of ovarian cancer. <i>Gynecologic Oncology</i> , 2009, 112, 275-281.	0.6	201
294	Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009. <i>Gynecologic Oncology</i> , 2009, 112, 444-449.	0.6	39

#	ARTICLE	IF	CITATIONS
295	Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma. <i>Gynecologic Oncology</i> , 2009, 112, 450-454.	0.6	21
296	Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2009, 112, 469-474.	0.6	80
297	Advanced cytoreductive surgery: American perspective. <i>Gynecologic Oncology</i> , 2009, 114, S3-S9.	0.6	36
298	Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies. <i>Gynecologic Oncology</i> , 2009, 113, 228-232.	0.6	18
299	Towards randomized trials of cytoreductive surgery using peritonectomy and hyperthermic intraperitoneal chemotherapy for ovarian cancer peritoneal carcinomatosis. <i>Gynecologic Oncology</i> , 2009, 114, 137-139.	0.6	19
300	In response to: "Towards randomized trials of peritonectomy and hyperthermic intraperitoneal chemotherapy for ovarian cancer peritoneal carcinomatosis". <i>Gynecologic Oncology</i> , 2009, 114, 139.	0.6	3
301	Intraperitoneal access via direct puncture is an alternative way to deliver intraperitoneal chemotherapy in ovarian, fallopian tube and primary peritoneal cancer. <i>Gynecologic Oncology</i> , 2009, 114, 42-47.	0.6	14
302	Practice patterns of intraperitoneal chemotherapy in women with ovarian cancer. <i>Gynecologic Oncology</i> , 2009, 114, 37-41.	0.6	31
303	Southwest Oncology Group Trial S9912: Intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer. <i>Gynecologic Oncology</i> , 2009, 114, 206-209.	0.6	11
304	Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer. <i>Gynecologic Oncology</i> , 2009, 114, 415-419.	0.6	23
305	Outcomes associated with different intraperitoneal chemotherapy delivery systems in advanced ovarian carcinoma: A single institution's experience. <i>Gynecologic Oncology</i> , 2009, 114, 420-423.	0.6	13
306	A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: An analysis of patients enrolled in GOG 172. <i>Gynecologic Oncology</i> , 2009, 115, 81-85.	0.6	24
307	A review of the current evidence for maintenance therapy in ovarian cancer. <i>Gynecologic Oncology</i> , 2009, 115, 290-301.	0.6	17
308	Association between the N-terminally truncated (Î ^N) p63 (Î ^N p63) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2009, 115, 424-429.	0.6	6
309	Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer model. <i>Gynecologic Oncology</i> , 2009, 115, 362-366.	0.6	30
311	Management of Women With Newly Diagnosed Ovarian Cancer. <i>Seminars in Oncology</i> , 2009, 36, 91-105.	0.8	5
312	The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma. <i>Cancer</i> , 2009, 115, 1028-1035.	2.0	79
313	CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers. <i>Cancer</i> , 2009, 115, 1395-1403.	2.0	68

#	ARTICLE	IF	CITATIONS
314	Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel. <i>Cancer</i> , 2009, 115, 4210-4217.	2.0	51
315	Evidence-based medicine in the treatment of peritoneal carcinomatosis: Past, present, and future. <i>Journal of Surgical Oncology</i> , 2009, 100, 335-344.	0.8	33
316	Clinical application of intraperitoneal chemotherapy before surgery for ovarian cancer and its evaluation. <i>Chinese-German Journal of Clinical Oncology</i> , 2009, 8, 260-264.	0.1	1
318	The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer. <i>Clinical and Translational Oncology</i> , 2009, 11, 753-759.	1.2	63
319	Current Status on Biologic Therapies in the Treatment of Epithelial Ovarian Cancer. <i>Current Treatment Options in Oncology</i> , 2009, 10, 54-66.	1.3	25
320	A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 799-805.	1.1	45
321	Enhancing the efficacy of cisplatin in ovarian cancer treatment – could arsenic have a role. <i>Journal of Ovarian Research</i> , 2009, 2, 2.	1.3	80
322	Intraperitoneal administration of paclitaxel solubilized with poly(2-methacryloxyethyl) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 504 <i>Cancer Science</i> , 2009, 100, 1979-1985.	1.7	55
323	Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Surface Malignancy: Non-Colorectal Indications. <i>Current Problems in Cancer</i> , 2009, 33, 168-193.	1.0	16
324	Chemotherapy for Gynecologic Cancers. <i>Mount Sinai Journal of Medicine</i> , 2009, 76, 577-588.	1.9	7
325	The antitumoral effect of Paris Saponin I associated with the induction of apoptosis through the mitochondrial pathway. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1179-1188.	1.9	53
326	Different Tissue Distribution of Paclitaxel With Intravenous and Intraperitoneal Administration. <i>Journal of Surgical Research</i> , 2009, 155, 142-146.	0.8	40
327	Rationale for perioperative chemotherapy treatment in peritoneal carcinomatosis. <i>CirugÃa EspaÃ±ola (English Edition)</i> , 2009, 85, 3-13.	0.1	2
328	Population Pharmacokinetics and Dosing Recommendations for Cisplatin during Intraperitoneal Perioperative Administration. <i>Clinical Pharmacokinetics</i> , 2009, 48, 169-180.	1.6	11
329	Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer. <i>World Journal of Surgical Oncology</i> , 2009, 7, 14.	0.8	30
331	Ovarian cancer. <i>Lancet, The</i> , 2009, 374, 1371-1382.	6.3	594
332	Cytoreductive surgery and perioperative intraperitoneal chemotherapy for the treatment of advanced primary and recurrent ovarian cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2009, 21, 15-24.	0.9	31
333	New therapeutic agents in ovarian cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2009, 21, 44-53.	0.9	17

#	ARTICLE	IF	CITATIONS
334	An Update on the Use of Intraperitoneal Chemotherapy in the Management of Ovarian Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2009, 15, 105-109.	1.0	16
335	Pharmacokinetics and Pharmacodynamics of Perioperative Cancer Chemotherapy in Peritoneal Surface Malignancy. <i>Cancer Journal (Sudbury, Mass)</i> , 2009, 15, 216-224.	1.0	81
336	Phase II Study of Intraperitoneal Carboplatin With Intravenous Paclitaxel in Patients With Suboptimal Residual Epithelial Ovarian or Primary Peritoneal Cancer. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 834-837.	1.2	20
337	Using Pharmacologic Data to Plan Clinical Treatments for Patients with Peritoneal Surface Malignancy. <i>Current Drug Discovery Technologies</i> , 2009, 6, 72-81.	0.6	36
338	Correlation of Extreme Drug Resistance Assay Results and Progression-Free Survival Following Intraperitoneal Chemotherapy for Advanced Ovarian Cancer. <i>Journal of Chemotherapy</i> , 2010, 22, 270-274.	0.7	5
339	Intraperitoneal Chemotherapy for Advanced Ovarian and Peritoneal Cancers in Patients Following Interval Debulking Surgery or Primary Cytoreductive Surgery: Tom Baker Cancer Centre Experience From 2006 to 2009. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2010, 32, 263-269.	0.3	6
340	First-line systemic treatment of ovarian cancer: a critical review of available evidence and expectations for future directions. <i>Current Opinion in Oncology</i> , 2010, 22, 513-520.	1.1	23
341	Ramirez's Abdominoplasty Technique Combined With Intraperitoneal Chemohyperthermia After Surgical Cytoreductive Procedures for the Treatment of Advanced Intraperitoneal Cancer in Patients With Ventral Hernia. <i>Annals of Plastic Surgery</i> , 2010, 64, 187-192.	0.5	3
342	Intraperitoneal Catheter Leads to Prolongation of the Time to Normalization of Serum CA125 Levels. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 932-935.	1.2	3
343	Factors Affecting the Completion of Intraperitoneal Chemotherapy in Women With Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 70-74.	1.2	13
344	CD44-Targeted Microparticles for Delivery of Cisplatin to Peritoneal Metastases. <i>Molecular Pharmaceutics</i> , 2010, 7, 280-290.	2.3	70
345	A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 293-301.	2.0	57
346	Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 745-753.	1.1	19
347	Epithelial ovarian carcinoma: current evidences and future perspectives in the first-line setting. <i>Clinical and Translational Oncology</i> , 2010, 12, 418-430.	1.2	6
348	Drug Delivery Systems for Intraperitoneal Therapy. <i>Pharmaceutical Research</i> , 2010, 27, 735-738.	1.7	94
349	Computed tomographic peritoneography prior to intraperitoneal chemotherapy in advanced malignant ovarian cancer: a pilot study. <i>Clinical Imaging</i> , 2010, 34, 191-195.	0.8	2
350	Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer. <i>Gynecologic Oncology</i> , 2010, 116, 340-344.	0.6	18
351	Completion of intraperitoneal chemotherapy in advanced ovarian cancer and catheter-related complications. <i>Gynecologic Oncology</i> , 2010, 116, 345-350.	0.6	29

#	ARTICLE	IF	CITATIONS
352	The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum. <i>Gynecologic Oncology</i> , 2010, 116, 351-357.	0.6	61
353	Achievements and unmet needs in the management of advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2010, 117, 152-158.	0.6	78
354	Targeted therapy in gynecologic oncology: Biology, strategy, and assessment. <i>Gynecologic Oncology</i> , 2010, 116, 155-156.	0.6	2
355	Translational research in the Gynecologic Oncology Group: Evaluation of ovarian cancer markers, profiles, and novel therapies. <i>Gynecologic Oncology</i> , 2010, 117, 429-439.	0.6	34
356	Reply to Dr. Markman on "Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer". <i>Gynecologic Oncology</i> , 2010, 117, 391.	0.6	0
357	The effect of age on the tolerability of intraperitoneal chemotherapy, complication rate, and survival in patients with ovarian cancer. <i>Gynecologic Oncology</i> , 2010, 119, 491-495.	0.6	24
358	Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer. <i>Journal of Surgical Oncology</i> , 2010, 101, 149-155.	0.8	57
359	Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer. <i>Journal of Surgical Oncology</i> , 2010, 102, 663-670.	0.8	67
360	The detection, treatment, and biology of epithelial ovarian cancer. <i>Journal of Ovarian Research</i> , 2010, 3, 8.	1.3	58
361	Intracavitary cisplatin therapy for pediatric malignancies. <i>Pediatric Blood and Cancer</i> , 2010, 55, 452-456.	0.8	3
362	Second-line treatment of first relapse recurrent ovarian cancer. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2010, 50, 465-471.	0.4	5
363	Locoregional intravascular viral therapy of cancer: precision guidance for Paris's arrow?. <i>Gene Therapy</i> , 2010, 17, 949-960.	2.3	8
364	Administration Guidelines for Intraperitoneal Chemotherapy for Ovarian Cancer. , 2010, , 89-94.		0
365	Management of ovarian and endometrial cancer in older adults. , 0, , 201-218.		1
366	A Current Review of Targeted Therapeutics for Ovarian Cancer. <i>Journal of Oncology</i> , 2010, 2010, 1-11.	0.6	45
367	Clinical trials and progress with paclitaxel in ovarian cancer. <i>International Journal of Women's Health</i> , 2010, 2, 411.	1.1	86
368	Predictors of Adjustment and Growth in Women With Recurrent Ovarian Cancer. <i>Oncology Nursing Forum</i> , 2010, 37, 357-364.	0.5	26
369	Review: Practical considerations in ovarian cancer chemotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2010, 2, 175-187.	1.4	74

#	ARTICLE	IF	CITATIONS
370	From randomized trial to practice: single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer. <i>Annals of Oncology</i> , 2010, 21, 1772-1778.	0.6	5
371	Intraperitoneal therapy for peritoneal cancer. <i>Future Oncology</i> , 2010, 6, 1625-1641.	1.1	141
372	Splenectomy in Cytoreductive Surgery for Advanced Ovarian Cancer and Subsequent Intraperitoneal Chemotherapy. <i>Journal of Gynecologic Surgery</i> , 2010, 26, 179-182.	0.0	0
373	Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 61-69.	1.2	87
374	The Gynecologic Oncology Group Ovarian Treatment Trials With Specimen Banking and Translational Research. <i>Clinical Ovarian Cancer & Other Gynecologic Malignancies</i> , 2010, 3, 98-112.	0.2	0
375	Handbook of Evidence-Based Radiation Oncology. , 2010, , .		45
377	The feasibility of carboplatin-based intraperitoneal chemotherapy in ovarian cancer. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2010, 152, 195-199.	0.5	14
378	Hyperthermic intra-peritoneal chemotherapy using Oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study. <i>European Journal of Surgical Oncology</i> , 2010, 36, 589-593.	0.5	70
379	Targeted Agents in Ovarian Cancer. <i>Women's Health</i> , 2010, 6, 679-694.	0.7	4
380	Intraperitoneal chemotherapy for ovarian cancer. <i>Community Oncology</i> , 2010, 7, 67-72.	0.2	2
381	IP chemotherapy for ovarian cancer: is the questionable benefit worth the added toxicity?. <i>Community Oncology</i> , 2010, 7, 73-74.	0.2	0
382	Intraperitoneal Therapy for Ovarian Cancer. , 2010, , .		0
383	Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhus gastric cancer cell line. <i>Journal of Experimental and Clinical Cancer Research</i> , 2010, 29, 149.	3.5	51
385	Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 108-115.	12.5	146
386	Current treatment and clinical trials in ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 521-534.	1.9	18
387	First-line treatment of advanced ovarian cancer: current research and perspectives. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 47-60.	1.1	84
388	Clinical Approach to Diagnosis and Management of Ovarian, Fallopian Tube, and Peritoneal Carcinoma. <i>Surgical Pathology Clinics</i> , 2011, 4, 261-274.	0.7	3
389	Outpatient Intraperitoneal Chemotherapy for All Stages of Ovarian, Fallopian Tube, and Peritoneal Cancers: A Pilot Study. <i>Clinical Ovarian Cancer & Other Gynecologic Malignancies</i> , 2011, 4, 7-11.	0.2	0

#	ARTICLE	IF	CITATIONS
390	Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. , 2011, , CD005340.		70
391	Molecular Targeted Therapy in Ovarian Cancer. <i>Drugs</i> , 2011, 71, 947-967.	4.9	14
392	A Phase 3 Trial of Bevacizumab in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2011, 365, 2484-2496.	13.9	1,843
393	Optimal primary surgical treatment for advanced epithelial ovarian cancer. <i>The Cochrane Library</i> , 2016, 2016, CD007565.	1.5	217
394	Chemotherapy in epithelial ovarian cancer. <i>Cancer Letters</i> , 2011, 303, 73-83.	3.2	83
395	Heterogeneity in patients and methods. A problem for hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in ovarian carcinoma. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2011, 158, 361-362.	0.5	25
396	Spontaneous conception and live birth after gonadotoxic chemotherapy for an aggressive bilateral ovarian Burkitt's lymphoma. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2011, 158, 362-364.	0.5	2
397	Gynecologic Malignancies. , 0, , 440-455.		0
398	Phase II/III Study of Intraperitoneal Chemotherapy after Neoadjuvant Chemotherapy for Ovarian Cancer: NCIC CTG OV.21. <i>Current Oncology</i> , 2011, 18, 84-90.	0.9	31
399	Bevacizumab in the treatment of ovarian cancer. <i>Biologics: Targets and Therapy</i> , 2011, 5, 1.	3.0	30
400	The Role of Surgery in the Management of Epithelial Ovarian Cancer. <i>Cancer Control</i> , 2011, 18, 22-30.	0.7	18
401	Current and Future Directions of Clinical Trials for Ovarian Cancer. <i>Cancer Control</i> , 2011, 18, 44-51.	0.7	17
402	A Review of Cost-Effectiveness Studies in Ovarian Cancer. <i>Cancer Control</i> , 2011, 18, 59-64.	0.7	34
403	Comparative Study of Grade 3/4 Toxicity Associated With Intraperitoneal Chemotherapy Administered After Primary Versus Interval Surgical Debulking in Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 811-815.	1.2	4
404	Which is the better surgical strategy for newly diagnosed epithelial ovarian cancer. <i>Current Opinion in Oncology</i> , 2011, 23, 501-506.	1.1	7
405	Functional Characterization of a Fluorescent Highly Tumorigenic Ovarian Cancer Line to Test Cellular Therapy in Experimental Models. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 457-465.	1.2	6
406	Feasibility of a Modified Outpatient Regimen of Intravenous/Intraperitoneal Chemotherapy in Optimally Debulked Stage III Ovarian Cancer Patients. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1048-1055.	1.2	11
407	Epithelial Ovarian Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 82-113.	2.3	89

#	ARTICLE	IF	CITATIONS
408	Intraperitoneal distribution imaging in ovarian cancer patients. <i>Internal Medicine Journal</i> , 2011, 41, 167-171.	0.5	3
409	Spatial distribution of intraperitoneally administrated paclitaxel nanoparticles solubilized with poly (2-methacryloxyethyl phosphorylcholine) butyl methacrylate) in peritoneal metastatic nodules. <i>Cancer Science</i> , 2011, 102, 200-205.	1.7	53
410	A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2011, 121, 264-268.	0.6	21
411	Does intraperitoneal chemotherapy benefit optimally debulked epithelial ovarian cancer patients after neoadjuvant chemotherapy?. <i>Gynecologic Oncology</i> , 2011, 121, 451-454.	0.6	11
412	HIPEC in recurrent ovarian cancer patients: Morbidity-related treatment and long-term analysis of clinical outcome. <i>Gynecologic Oncology</i> , 2011, 122, 221-225.	0.6	61
413	The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: A gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2011, 122, 521-526.	0.6	59
414	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: Multi-institutional phase-II trial. <i>Gynecologic Oncology</i> , 2011, 122, 215-220.	0.6	131
415	Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2011, 122, 473-478.	0.6	37
416	Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer. <i>Gynecologic Oncology</i> , 2011, 122, 527-531.	0.6	12
417	Intraperitoneal administration of novel doxorubicin loaded polymeric delivery systems against peritoneal carcinomatosis: Experimental study in a murine model of ovarian cancer. <i>Gynecologic Oncology</i> , 2011, 122, 632-640.	0.6	14
418	Is hyperthermic intraoperative peritoneal chemotherapy and systemic chemotherapy as effective as standard intraperitoneal chemotherapy: time for a prospective trial?. <i>Gynecologic Oncology</i> , 2011, 122, 207-208.	0.6	2
419	Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2011, 123, 182-186.	0.6	15
420	It's not just for laparoscopy anymore: Use of insufflation under ultrasound and fluoroscopic guidance by Interventional Radiologists for percutaneous placement of intraperitoneal chemotherapy catheters. <i>Gynecologic Oncology</i> , 2011, 123, 342-345.	0.6	9
421	The regulation of MASPIN expression in epithelial ovarian cancer: Association with p53 status, and MASPIN promoter methylation: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2011, 123, 314-319.	0.6	11
422	Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial. <i>Trials</i> , 2011, 12, 129.	0.7	18
423	Recent progress in the diagnosis and treatment of ovarian cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2011, 61, 183-203.	157.7	618
424	Neoadjuvant Intraperitoneal and Systemic Chemotherapy for Gastric Cancer Patients with Peritoneal Dissemination. <i>Annals of Surgical Oncology</i> , 2011, 18, 3726-3731.	0.7	54
425	Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 5-11.	1.1	16

#	ARTICLE	IF	CITATIONS
426	Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 457-463.	1.1	8
427	Neoadjuvant intraperitoneal chemotherapy with paclitaxel for the radical surgical treatment of peritoneal carcinomatosis in ovarian cancer: a prospective pilot study. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 267-274.	1.1	26
428	Safety, feasibility and effects of an individualised walking intervention for women undergoing chemotherapy for ovarian cancer: a pilot study. <i>BMC Cancer</i> , 2011, 11, 389.	1.1	53
429	Peritoneal carcinomatosis from ovarian cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapy. <i>Journal of Translational Medicine</i> , 2011, 9, 94.	1.8	15
430	Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: A pilot study of 31 patients. <i>Journal of Surgical Oncology</i> , 2011, 103, 10-16.	0.8	46
432	Place de la chimiothérapie hyperthermique intrapéritonéale (CHIP) dans la prise en charge du cancer de l'ovaire : expérience monocentrique institutionnelle. <i>Bulletin Du Cancer</i> , 2011, 98, 633-643.	0.6	1
434	Effective Delivery of PEGylated siRNA-Containing Lipoplexes to Extraperitoneal Tumours following Intraperitoneal Administration. <i>Journal of Drug Delivery</i> , 2011, 2011, 1-7.	2.5	12
435	Cytotoxic Effect of Hyperthermia and Chemotherapy with Platinum Salt on Ovarian Cancer Cells: Results of an in vitro Study. <i>European Surgical Research</i> , 2011, 46, 139-147.	0.6	14
436	A Randomized Phase II/III Trial of 3 Weekly Intraperitoneal versus Intravenous Carboplatin in Combination with Intravenous Weekly Dose-dense Paclitaxel for Newly Diagnosed Ovarian, Fallopian Tube and Primary Peritoneal Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 278-282.	0.6	34
437	Feasibility of Intravenous Gemcitabine and an Intraperitoneal Platinum Agent in the Treatment of Ovarian Cancer. <i>Journal of Chemotherapy</i> , 2011, 23, 163-167.	0.7	2
438	Phase II Study of Intraperitoneal Paclitaxel Plus Cisplatin and Intravenous Paclitaxel Plus Bevacizumab As Adjuvant Treatment of Optimal Stage II/III Epithelial Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4662-4668.	0.8	43
439	Pharmacokinetics of the Perioperative Use of Cancer Chemotherapy in Peritoneal Surface Malignancy Patients. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-9.	0.7	19
440	Minireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing Therapy. <i>Endocrinology</i> , 2012, 153, 1593-1602.	1.4	248
441	A Rational Approach to the Management of Recurrent or Persistent Ovarian Carcinoma. <i>Clinical Obstetrics and Gynecology</i> , 2012, 55, 114-130.	0.6	30
442	Phase I Trial of Intraperitoneal Pemetrexed, Cisplatin, and Paclitaxel in Optimally Debulked Ovarian Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 2668-2678.	3.2	32
443	Cellular Therapy for Ovarian Cancer: Experimental and Clinical Perspectives. <i>Current Medicinal Chemistry</i> , 2012, 19, 3787-3793.	1.2	7
444	Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study. <i>British Journal of Cancer</i> , 2012, 106, 460-467.	2.9	11
445	Doublet Chemotherapy in the Elderly Patient With Ovarian Cancer. <i>Oncologist</i> , 2012, 17, 1450-1460.	1.9	11

#	ARTICLE	IF	CITATIONS
446	Adjuvant Bidirectional Chemotherapy Using an Intraperitoneal Port. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-5.	0.7	19
447	Evolution of the Gynecologic Oncology Group Protocols in the Treatment of Epithelial Ovarian Cancer. <i>Clinical Obstetrics and Gynecology</i> , 2012, 55, 131-155.	0.6	9
448	Percutaneous Insertion of Peritoneal Ports. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 328-331.	1.2	2
449	Survival Benefit of Adding Hyperthermic IntraPERitoneal Chemotherapy (HIPEC) at the Different Time-points of Treatment of Ovarian Cancer: Review of Evidence. <i>Current Pharmaceutical Design</i> , 2012, 18, 3793-3803.	0.9	63
450	Editorial: Advances in Epithelial Ovarian Cancer Therapy. <i>Current Pharmaceutical Design</i> , 2012, 18, 3735-3740.	0.9	10
451	One Port Laparoscopic Technique for Interval Placement of Intraperitoneal Chemotherapy Port Under Direct Visualization. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2012, 22, e12-e14.	0.4	1
452	Delayed Repeated Intraperitoneal Chemotherapy After Cytoreductive Surgery for Colorectal and Appendiceal Carcinomatosis. <i>Diseases of the Colon and Rectum</i> , 2012, 55, 1044-1052.	0.7	7
453	Expanding Surgical Treatment of Pancreatic Cancer. <i>Pancreas</i> , 2012, 41, 678-684.	0.5	15
454	Intraperitoneal Chemotherapy for Recurrent Epithelial Ovarian Cancer Is Feasible With High Completion Rates, Low Complications, and Acceptable Patient Outcomes. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 232-237.	1.2	13
455	Extraperitoneal Metastases From Recurrent Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 43-46.	1.2	22
456	Intraperitoneal Chemotherapy by Ultrasound-Guided Direct Puncture in Recurrent Ovarian Cancer: Feasibility, Compliance, and Complications. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 1069-1074.	1.2	11
457	Intravenous/Intraperitoneal Paclitaxel and Intraperitoneal Carboplatin in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma: A Feasibility Study. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 70-75.	1.2	12
458	Recent advances in drug delivery strategies for treatment of ovarian cancer. <i>Expert Opinion on Drug Delivery</i> , 2012, 9, 567-583.	2.4	39
459	Potent therapeutic activity of folate receptor-targeted liposomal carboplatin in the localized treatment of intraperitoneally grown human ovarian tumor xenograft. <i>International Journal of Nanomedicine</i> , 2012, 7, 739.	3.3	30
460	Cancer of the ovary, fallopian tube, and peritoneum. <i>International Journal of Gynecology and Obstetrics</i> , 2012, 119, S118-29.	1.0	194
461	Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy. <i>Gynecologic Oncology</i> , 2012, 127, 51-54.	0.6	24
462	A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2012, 127, 506-510.	0.6	14
463	Intraperitoneal Catheter Placement: The "Hammock" Technique. <i>Clinical Ovarian and Other Gynecologic Cancer</i> , 2012, 5, 24-26.	0.1	3

#	ARTICLE	IF	CITATIONS
464	Epithelial Ovarian Cancer. <i>Obstetrics and Gynecology Clinics of North America</i> , 2012, 39, 269-283.	0.7	8
465	Improving therapeutic effect in ovarian peritoneal carcinomatosis with honokiol nanoparticles in a thermosensitive hydrogel composite. <i>RSC Advances</i> , 2012, 2, 7759.	1.7	13
466	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Persistent and Recurrent Advanced Ovarian Carcinoma: A Multicenter, Prospective Study of 246 Patients. <i>Annals of Surgical Oncology</i> , 2012, 19, 4052-4058.	0.7	96
467	Epithelial Ovarian Cancer. , 2012, , 285-328.e12.		10
468	Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2012, 119, 800-809.	1.1	68
471	PEGylated liposome IHL-305 markedly improved the survival of ovarian cancer peritoneal metastasis in mouse. <i>BMC Cancer</i> , 2012, 12, 462.	1.1	7
472	Pharmacokinetics and Pharmacodynamics of Intraperitoneal Cancer Chemotherapeutics. <i>Clinical Pharmacokinetics</i> , 2012, 51, 203-224.	1.6	72
473	Intraperitoneal chemotherapy in older women with epithelial ovarian cancer. <i>Journal of Geriatric Oncology</i> , 2012, 3, 189-195.	0.5	16
474	Intraperitoneal chemotherapy in epithelial ovarian cancer: Do we know the best way to do it?. <i>Journal of Geriatric Oncology</i> , 2012, 3, 386-387.	0.5	0
475	Abandoning TAP as Treatment of Metastatic Endometrial Cancer: A Serious Example of the Consequences Resulting from the Failure To Adequately Define the Question Being Addressed in a Phase 3 Trial. <i>Current Oncology Reports</i> , 2012, 14, 480-482.	1.8	0
476	Ovarian Cancer: Advances in First-Line Treatment Strategies with a Particular Focus on Anti-Angiogenic Agents. <i>Current Oncology Reports</i> , 2012, 14, 509-518.	1.8	9
478	Pharmacology of Perioperative Intraperitoneal and Intravenous Chemotherapy in Patients with Peritoneal Surface Malignancy. <i>Surgical Oncology Clinics of North America</i> , 2012, 21, 577-597.	0.6	39
479	Hyperthermic intraperitoneal chemotherapy in ovarian cancer: rationale and clinical data. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 895-911.	1.1	23
480	Intraperitoneal Chemotherapy for Epithelial Ovarian Cancer – Single Center Experience. <i>Indian Journal of Surgical Oncology</i> , 2012, 3, 262-266.	0.3	3
481	Intraperitoneal Chemotherapy for Ovarian Cancer. <i>Oncology Nursing Forum</i> , 2012, 39, 346-349.	0.5	0
483	Three ongoing intraperitoneal chemotherapy trials in ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2012, 23, 75.	1.0	17
484	Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2012, 23, 91.	1.0	9
485	Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2012, 23, 265.	1.0	192

#	ARTICLE	IF	CITATIONS
486	Recent advances in systemic treatments for ovarian cancer. <i>Cancer Imaging</i> , 2012, 12, 305-309.	1.2	7
487	Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy. <i>Cancer Management and Research</i> , 2012, 4, 413.	0.9	39
488	Angiogenesis: A promising therapeutic target for ovarian cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, 314-326.	2.0	37
489	Ports and complications for intraperitoneal chemotherapy delivery. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2012, 119, 150-159.	1.1	27
490	Upper abdominal cytoreduction and thoracoscopy for advanced epithelial ovarian cancer: unanswered questions and the impact on treatment. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2012, 119, 202-206.	1.1	10
491	Peritoneal surface malignancies and regional treatment: A review of the literature. <i>Surgical Oncology</i> , 2012, 21, 87-94.	0.8	27
492	An injectable depot system for sustained intraperitoneal chemotherapy of ovarian cancer results in favorable drug distribution at the whole body, peritoneal and intratumoral levels. <i>Journal of Controlled Release</i> , 2012, 158, 379-385.	4.8	29
493	Intraperitoneal delivery of paclitaxel with injectable hydrogel: "Seeing is not always believing". <i>Journal of Controlled Release</i> , 2012, 158, 355.	4.8	5
494	Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer. <i>Gynecologic Oncology</i> , 2012, 124, 59-62.	0.6	32
495	CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: A gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2012, 124, 216-220.	0.6	6
496	A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2012, 125, 54-58.	0.6	14
497	Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: Redefining "optimal" residual disease. <i>Gynecologic Oncology</i> , 2012, 125, 483-492.	0.6	152
498	Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer. <i>Gynecologic Oncology</i> , 2012, 125, 625-630.	0.6	28
499	Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer. <i>Gynecologic Oncology</i> , 2012, 125, 621-624.	0.6	46
500	Cytoreduction and Hyperthermic Intraperitoneal Chemoperfusion in Women with Heavily Pretreated Recurrent Ovarian Cancer. <i>Annals of Surgical Oncology</i> , 2012, 19, 2352-2359.	0.7	45
501	Intraperitoneal docetaxel combined with S1 for advanced gastric cancer with peritoneal dissemination. <i>Journal of Surgical Oncology</i> , 2012, 105, 38-42.	0.8	60
502	Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: A pilot study. <i>Gynecologic Oncology</i> , 2013, 129, 81-85.	0.6	30
503	Current standards of care for chemotherapy of optimally cytoreduced advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2013, 131, 241-245.	0.6	27

#	ARTICLE	IF	CITATIONS
505	Considerations Regarding the Administration of Systemic Therapy for Elderly Patients With Ovarian Cancer. <i>Current Treatment Options in Oncology</i> , 2013, 14, 1-11.	1.3	4
506	Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: A meta-analysis. <i>Gynecologic Oncology</i> , 2013, 130, 493-498.	0.6	338
507	Principle and evolving role of intraperitoneal chemotherapy in ovarian cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1797-1806.	0.9	12
508	Management of Gynecological Cancers in Older Women. , 2013, , .		2
509	Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: A French multicentre retrospective cohort study of 566 patients. <i>European Journal of Surgical Oncology</i> , 2013, 39, 1435-1443.	0.5	234
510	Evaluation of exposures to healthcare personnel from cisplatin during a mock demonstration of intra-operative intraperitoneal chemotherapy administration. <i>Gynecologic Oncology</i> , 2013, 130, 350-353.	0.6	6
511	Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2013, 130, 12-18.	0.6	127
512	Randomized, Phase II, Placebo-Controlled, Double-Blind Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin As First-Line Treatment Followed by Maintenance Treatment in Advanced Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3127-3132.	0.8	25
513	Bevacizumab and ovarian cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2013, 5, 133-141.	1.4	45
514	Paclitaxel-loaded polymeric microparticles: Quantitative relationships between in vitro drug release rate and in vivo pharmacodynamics. <i>Journal of Controlled Release</i> , 2013, 172, 737-744.	4.8	35
515	Phase II study of interval debulking surgery followed by intraperitoneal chemotherapy for advanced ovarian cancer: A Kansai Clinical Oncology Group study (KCOG9812). <i>Gynecologic Oncology</i> , 2013, 128, 22-27.	0.6	5
516	Evolving concepts in the management of drug resistant ovarian cancer: Dose dense chemotherapy and the reversal of clinical platinum resistance. <i>Cancer Treatment Reviews</i> , 2013, 39, 153-160.	3.4	53
517	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: Upfront therapy, at first recurrence, or later?. <i>European Journal of Surgical Oncology</i> , 2013, 39, 1109-1115.	0.5	45
519	Optimizing management tools for ovarian cancer improves survival. <i>Gynecologic Oncology</i> , 2013, 130, 1-2.	0.6	7
520	Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2013, 129, 74-80.	0.6	75
521	BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. <i>British Journal of Cancer</i> , 2013, 108, 1231-1237.	2.9	120
522	GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012. <i>Clinical and Translational Oncology</i> , 2013, 15, 509-525.	1.2	9
523	Continuous Intraperitoneal Carboplatin Delivery for the Treatment of Late-Stage Ovarian Cancer. <i>Molecular Pharmaceutics</i> , 2013, 10, 3315-3322.	2.3	8

#	ARTICLE	IF	CITATIONS
526	Intraperitoneal chemotherapy requires expertise and should be the standard of care for optimally surgically resected epithelial ovarian cancer patients. <i>Annals of Oncology</i> , 2013, 24, x41-x45.	0.6	6
527	Safety and Outcome of Patients Treated with a Modified Outpatient Intraperitoneal Regimen for Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer. <i>Chemotherapy</i> , 2013, 59, 251-259.	0.8	8
528	Monoclonal antibodies therapies for ovarian cancer. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 739-764.	1.4	21
529	Low-dose paclitaxel modulates tumour fibrosis in gastric cancer. <i>International Journal of Oncology</i> , 2013, 42, 1167-1174.	1.4	42
530	Advanced ovarian cancer: what should be the standard of care?. <i>Journal of Gynecologic Oncology</i> , 2013, 24, 83.	1.0	40
531	Use and Interpretation of the National Comprehensive Cancer Network- Functional Assessment of Cancer Therapy Symptom Indexes in Palliative Research and Treatment: Special Considerations in Ovarian Cancer. <i>Journal of Palliative Care & Medicine</i> , 2013, 03, .	0.1	3
532	Update on first-line treatment of advanced ovarian carcinoma. <i>International Journal of Women's Health</i> , 2013, 5, 45.	1.1	32
533	Indikationen und Resultate der Peritonektomie bei nichtkolorektaler Peritonealkarzinose. <i>Viszeralmedizin</i> , 2013, 29, 235-244.	0.0	1
534	Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study. <i>Journal of Gynecologic Oncology</i> , 2013, 24, 359.	1.0	16
535	Chemotherapy of ovarian cancer. , 0, , 415-424.		1
536	Intra-peritoneal chemotherapy. , 0, , 425-430.		0
537	Major clinical research advances in gynecologic cancer in 2013. <i>Journal of Gynecologic Oncology</i> , 2014, 25, 236.	1.0	30
538	Diffusion of Intraperitoneal Chemotherapy in Women with Advanced Ovarian Cancer in Community Settings 2003-2008: The Effect of the NCI Clinical Recommendation. <i>Frontiers in Oncology</i> , 2014, 4, 43.	1.3	15
539	Survival outcomes and toxicity of intraoperative intraperitoneal chemotherapy in advanced epithelial ovarian cancer. <i>Obstetrics and Gynecology Science</i> , 2014, 57, 484.	0.6	6
541	SEOM guideline in ovarian cancer 2014. <i>Clinical and Translational Oncology</i> , 2014, 16, 1067-1071.	1.2	13
542	The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1105-1113.	1.1	2
543	Metronomic Chemotherapy. , 2014, , .		3
544	Peritoneal debulking/intraperitoneal chemotherapy in non-sarcoma. <i>Journal of Surgical Oncology</i> , 2014, 109, 14-22.	0.8	13

#	ARTICLE	IF	CITATIONS
545	Outcomes with cytoreductive surgery and HIPEC for peritoneal metastasis. <i>Journal of Surgical Oncology</i> , 2014, 110, 575-584.	0.8	44
546	HIPEC ROC I: A phase i study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer. <i>International Journal of Cancer</i> , 2015, 136, 699-708.	2.3	75
547	Current treatment options and drug delivery systems as potential therapeutic agents for ovarian cancer: A review. <i>Materials Science and Engineering C</i> , 2014, 45, 609-619.	3.8	62
548	Debulking Surgery and Intraperitoneal Chemotherapy Are Associated With Decreased Morbidity in Women Receiving Neoadjuvant Chemotherapy for Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 43-47.	1.2	3
549	Does Modality of Adjuvant Chemotherapy After Interval Surgical Debulking Matter in Epithelial Ovarian Cancer?: An Exploratory Analysis. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 461-467.	1.2	7
550	Tumor priming enhances siRNA delivery and transfection in intraperitoneal tumors. <i>Journal of Controlled Release</i> , 2014, 178, 79-85.	4.8	30
551	Advances in Diagnosis and Management of Ovarian Cancer. , 2014, , .		3
552	Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. <i>Gynecologic Oncology</i> , 2014, 132, 8-17.	0.6	65
553	Multiscale Tumor Spatiokinetic Model for Intraperitoneal Therapy. <i>AAPS Journal</i> , 2014, 16, 424-439.	2.2	29
554	Intraperitoneal Chemotherapy from Armstrong to HIPEC: Challenges and Promise. <i>Current Treatment Options in Oncology</i> , 2014, 15, 27-40.	1.3	8
556	Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer. <i>Surgery Today</i> , 2014, 44, 2209-2220.	0.7	19
557	Hyperthermic Intra-Thoracic Chemotherapy (HITeC) for the management of recurrent ovarian cancer involving the pleural cavity. <i>Gynecologic Oncology Case Reports</i> , 2014, 9, 24-25.	0.9	6
558	Single compartment drug delivery. <i>Journal of Controlled Release</i> , 2014, 190, 157-171.	4.8	46
559	Cytoreductive Surgery for Advanced Ovarian Cancer. <i>Women's Health</i> , 2014, 10, 179-190.	0.7	12
560	La chimiohyperthermie intrapéritonéale (CHIP) dans les cancers ovariens. <i>Journal De Chirurgie Viscérale</i> , 2014, 151, 358-365.	0.0	3
561	Hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. <i>Journal of Visceral Surgery</i> , 2014, 151, 347-353.	0.4	46
562	Biological Activity of Resveratrol on an Ovarian Cancer Cell. , 2014, , 1257-1268.		0
563	Intraperitoneal chemotherapy in advanced epithelial ovarian cancer: a survey. <i>Archives of Gynecology and Obstetrics</i> , 2014, 290, 425-434.	0.8	6

#	ARTICLE	IF	CITATIONS
564	Ovarian Cancer: A Brief Historical Overview of Intraperitoneal Trials. <i>Annals of Surgical Oncology</i> , 2014, 21, 1429-1434.	0.7	8
565	The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer relapse. <i>Updates in Surgery</i> , 2014, 66, 109-113.	0.9	9
566	A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 134, 468-472.	0.6	10
567	Intraperitoneal chemotherapy against peritoneal carcinomatosis. <i>Surgical Oncology</i> , 2014, 23, 99-106.	0.8	35
568	The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2014, 132, 560-565.	0.6	50
570	Prognostic Significance of the Number of Postoperative Intraperitoneal Chemotherapy Cycles for Patients With Advanced Epithelial Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 599-606.	1.2	13
571	Development of drug-loaded particles for intraperitoneal therapy. , 2015, , 331-343.		3
574	Ovarian cancer standard of care: are there real alternatives?. <i>Chinese Journal of Cancer</i> , 2015, 34, 17-27.	4.9	79
576	Practicing What We Preach!. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 123-124.	2.3	0
577	Prediction of Optimal Cytoreductive Surgery of Serous Ovarian Cancer With Gene Expression Data. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1000-1009.	1.2	6
578	Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1548-1557.	2.1	70
579	Therapeutic Innovations in Ovarian Cancer Treatment: The New England Perspective. <i>Gynecology & Obstetrics (Sunnyvale, Calif)</i> , 2015, 05, .	0.1	0
580	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer. <i>Case Studies in Surgery</i> , 2015, 2, .	0.0	0
581	Theoretical Considerations for Optimal Cytoreductive Surgery Plus Hyperthermic Perioperative Chemotherapy. , 2015, 05, .		1
582	Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study. <i>Journal of Gynecologic Oncology</i> , 2015, 26, 54.	1.0	71
583	Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer. <i>BioMed Research International</i> , 2015, 2015, 1-21.	0.9	227
584	Feasibility and Safety of a Modified Outpatient Regimen With Intravenous/Intraperitoneal Chemotherapy for Optimally Debulked Stage III Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 214-221.	1.2	5
585	Addition of bevacizumab to chemotherapy in patients with ovarian cancer: a systematic review and meta-analysis of randomized trials. <i>Clinical and Translational Oncology</i> , 2015, 17, 673-683.	1.2	21

#	ARTICLE	IF	CITATIONS
586	Neoadjuvant and Adjuvant Chemotherapy for Advanced Ovarian Cancer, Including Biological Agents. , 2015, , 441-453.		0
587	Comparative Effectiveness Research in Gynecologic Oncology. Cancer Treatment and Research, 2015, 164, 237-259.	0.2	0
588	A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax [®]) in patients with peritoneal malignancies. Cancer Chemotherapy and Pharmacology, 2015, 75, 1075-1087.	1.1	55
589	Looking up: Recent advances in understanding and treating peritoneal carcinomatosis. Ca-A Cancer Journal for Clinicians, 2015, 65, 283-298.	157.7	105
590	Differentiation between benign and malignant ovarian masses in the preoperative period using neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios. Molecular and Clinical Oncology, 2015, 3, 317-321.	0.4	25
591	Treatment of ovarian cancer in the older woman. Gynecologic Oncology, 2015, 136, 136-142.	0.6	30
592	Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival. Gynecologic Oncology, 2015, 136, 121-129.	0.6	12
594	HIPEC in ovarian cancer: Treatment of a new era or is it the end of the pipeline?. Gynecologic Oncology, 2015, 139, 363-368.	0.6	12
595	A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2015, 138, 36-40.	0.6	6
596	Toxicity of intraperitoneal chemotherapy and risk factors for severe toxicity in optimally debulked ovarian cancer patients. Taiwanese Journal of Obstetrics and Gynecology, 2015, 54, 275-279.	0.5	3
597	Versatility of Particulate Carriers: Development of Pharmacodynamically Optimized Drug-Loaded Microparticles for Treatment of Peritoneal Cancer. AAPS Journal, 2015, 17, 1065-1079.	2.2	17
598	The Role of Systemic Chemotherapy. Updates in Surgery Series, 2015, , 179-194.	0.0	0
599	New Trials. Updates in Surgery Series, 2015, , 375-393.	0.0	0
600	Rationale for Integrated Procedures: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined. Updates in Surgery Series, 2015, , 107-127.	0.0	0
601	Biological intensity-modulated radiotherapy plus neoadjuvant chemotherapy for multiple peritoneal metastases of ovarian cancer: A case report. Oncology Letters, 2015, 9, 1239-1243.	0.8	9
602	Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancers: Is there a role?. Gynecologic Oncology, 2015, 137, 184.	0.6	0
603	Intraperitoneal Chemotherapy: Long-Term Outcomes Revive a Long-Running Debate. Journal of Clinical Oncology, 2015, 33, 1424-1426.	0.8	10
604	Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study. Journal of Clinical Oncology, 2015, 33, 1460-1466.	0.8	243

#	ARTICLE	IF	CITATIONS
605	Cancer of the ovary, fallopian tube, and peritoneum. International Journal of Gynecology and Obstetrics, 2015, 131, S111-22.	1.0	70
606	Phase I study of intravenous (IV) docetaxel and intraperitoneal (IP) oxaliplatin in recurrent ovarian and fallopian tube cancer. Gynecologic Oncology, 2015, 138, 548-553.	0.6	5
607	Complications of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Advanced Ovarian Malignancies: First Indian Study. Indian Journal of Gynecologic Oncology, 2015, 13, 1.	0.1	0
608	Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer. Journal of Clinical Oncology, 2015, 33, 2841-2847.	0.8	159
609	Quantifying and reducing uncertainties in cancer therapy. , 2015, 9412, .		2
610	The Next Steps in Improving the Outcomes of Advanced Ovarian Cancer. Women's Health, 2015, 11, 355-367.	0.7	8
611	A review of HER2-targeted therapy in breast and ovarian cancer: lessons from antiquity â€œ CLEOPATRA and PENELOPE. Future Oncology, 2015, 11, 3113-3131.	1.1	17
612	Dose-dense Paclitaxel in Advanced Ovarian Cancer. Clinical Oncology, 2015, 27, 40-47.	0.6	25
613	Treatment of Peritoneal Surface Malignancies with Hyperthermic Intraperitoneal Chemotherapyâ€”Current Perspectives. Current Oncology, 2016, 23, 266-275.	0.9	55
614	Update on Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 143-151.	1.8	22
615	Preoperative intraperitoneal oxaliplatin for unresectable peritoneal carcinomatosis of colorectal origin: a pilot study. Pleura and Peritoneum, 2016, 1, 209-215.	0.5	11
616	Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer. International Journal of Gynecological Cancer, 2016, 26, 626-631.	1.2	6
617	Interval Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in First-Line Treatment for Advanced Ovarian Carcinoma: A Feasibility Study. International Journal of Gynecological Cancer, 2016, 26, 912-917.	1.2	10
618	Utilization and Toxicity of Alternative Delivery Methods of Adjuvant Chemotherapy for Ovarian Cancer. Obstetrics and Gynecology, 2016, 127, 985-991.	1.2	22
619	Intraperitoneal Therapy for Ovarian Cancer. Journal of Clinical Oncology, 2016, 34, 882-882.	0.8	3
620	Intraperitoneal chemotherapy of ovarian cancer by hydrogel depot of paclitaxel nanocrystals. Journal of Controlled Release, 2016, 235, 91-98.	4.8	42
621	Targeted Therapy in Ovarian Cancer. Women's Health, 2016, 12, 363-378.	0.7	28
622	Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center. Gynecologic Oncology, 2016, 142, 13-18.	0.6	2

#	ARTICLE	IF	CITATIONS
624	Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Methodology, Drugs and Bidirectional Chemotherapy. <i>Indian Journal of Surgical Oncology</i> , 2016, 7, 152-159.	0.3	37
625	The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review. <i>Indian Journal of Surgical Oncology</i> , 2016, 7, 188-197.	0.3	45
626	Therapy operating characteristic curves: tools for precision chemotherapy. <i>Journal of Medical Imaging</i> , 2016, 3, 023502.	0.8	5
627	Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center. <i>Gynecologic Oncology</i> , 2016, 143, 496-503.	0.6	12
628	Ovarian cancer in the older woman. <i>Journal of Geriatric Oncology</i> , 2016, 7, 354-361.	0.5	60
629	Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 3460-3473.	0.8	318
630	Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. <i>Gynecologic Oncology</i> , 2016, 143, 3-15.	0.6	208
631	First-Line Chemotherapy for Ovarian Cancer: Inferences From Recent Studies. <i>Oncologist</i> , 2016, 21, 1286-1290.	1.9	2
632	Update on chemotherapy in gynaecological cancers. <i>The Obstetrician and Gynaecologist</i> , 2016, 18, 182-188.	0.2	8
633	Experimental study of antitumour activity and effects on leukocyte count of intraperitoneal administration and hyperthermic intraperitoneal chemoperfusion (HIPEC) with dioxadet in a rat model of ovarian cancer. <i>Journal of Chemotherapy</i> , 2016, 28, 203-209.	0.7	7
634	Discovery of candidate tumor biomarkers for treatment with intraperitoneal chemotherapy for ovarian cancer. <i>Scientific Reports</i> , 2016, 6, 21591.	1.6	18
635	Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study. <i>Gynecologic Oncology</i> , 2016, 143, 484-489.	0.6	6
636	Synergistic effect of piperine and paclitaxel on cell fate via cyt-c, Bax/Bcl-2-caspase-3 pathway in ovarian adenocarcinomas SKOV-3 cells. <i>European Journal of Pharmacology</i> , 2016, 791, 751-762.	1.7	47
637	The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: An introduction of the peritoneal surface disease severity score. <i>Journal of Surgical Oncology</i> , 2016, 114, 779-784.	0.8	21
638	Fifth annual workshop of cytoreductive surgery for advanced ovarian cancer and peritoneal surface malignancies. <i>Gynecologic Oncology Research and Practice</i> , 2016, 3, 10.	3.6	1
639	Intraperitoneal-Free Cancer Cells Represent a Major Prognostic Factor in Colorectal Peritoneal Carcinomatosis. <i>Diseases of the Colon and Rectum</i> , 2016, 59, 615-622.	0.7	15
640	Reply to G.B. Holt. <i>Journal of Clinical Oncology</i> , 2016, 34, 1016-1017.	0.8	0
641	Second-Line Intraperitoneal Chemotherapy for Recurrent Epithelial Ovarian, Tubal and Peritoneal Cancer: A Propensity Score-Matching Study. <i>Chemotherapy</i> , 2016, 61, 240-248.	0.8	3

#	ARTICLE	IF	CITATIONS
642	Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study. <i>Chinese Journal of Cancer</i> , 2016, 35, 45.	4.9	0
643	Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. <i>Gynecologic Oncology</i> , 2016, 140, 436-442.	0.6	97
644	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer. <i>International Journal of Hyperthermia</i> , 2016, 32, 298-310.	1.1	23
645	Front-line intraperitoneal versus intravenous chemotherapy in stage III-IV epithelial ovarian, tubal, and peritoneal cancer with minimal residual disease: a competing risk analysis. <i>BMC Cancer</i> , 2016, 16, 235.	1.1	5
646	Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. <i>The Cochrane Library</i> , 2016, 2016, CD005340.	1.5	137
647	Reply to F.M. Muggia. <i>Journal of Clinical Oncology</i> , 2016, 34, 882-883.	0.8	0
648	Chemotherapy: First-Line Strategy. , 2016, , 49-61.		0
649	A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 333-338.	1.1	10
650	Ovarian Cancer in Elderly Patients. , 2016, , .		1
652	Multifunctional platinum-based nanoparticles for biomedical applications. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2017, 9, e1410.	3.3	50
653	An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Practice, 2017, 23, 454-469.	0.5	9
654	Targeting the extracellular matrix of ovarian cancer using functionalized, drug loaded lyophilisomes. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2017, 113, 229-239.	2.0	26
655	Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. <i>European Journal of Surgical Oncology</i> , 2017, 43, 1228-1235.	0.5	70
656	Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?. <i>Gynecologic Oncology</i> , 2017, 145, 15-20.	0.6	55
657	A phase 1/2a, dose-escalation, safety, pharmacokinetic, and preliminary efficacy study of intraperitoneal administration of BC-819 (H19-DTA) in subjects with recurrent ovarian/peritoneal cancer. <i>Archives of Gynecology and Obstetrics</i> , 2017, 295, 751-761.	0.8	40
658	The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer. <i>Inflammation Research</i> , 2017, 66, 467-475.	1.6	45
660	Profound sensorineural hearing loss after one cycle of intraperitoneal cisplatin in treatment of advanced ovarian cancer. <i>Gynecologic Oncology Reports</i> , 2017, 20, 103-104.	0.3	5
661	NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 145, 420-425.	0.6	61

#	ARTICLE	IF	CITATIONS
662	Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy in the Management of Colorectal Peritoneal Metastasis. <i>Surgical Clinics of North America</i> , 2017, 97, 671-682.	0.5	26
663	Ovarian cancer spheroid shrinkage following continuous exposure to cisplatin is a function of spheroid diameter. <i>Gynecologic Oncology</i> , 2017, 146, 161-169.	0.6	13
665	Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2017, 146, 137-145.	0.6	4
666	Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases. <i>Annals of Surgical Oncology</i> , 2017, 24, 914-922.	0.7	78
667	Hyperthermic intraperitoneal chemoperfusion as a component of multimodality therapy for ovarian and primary peritoneal cancer. <i>Journal of Surgical Oncology</i> , 2017, 116, 320-328.	0.8	11
668	Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women. <i>Gynecologic Oncology</i> , 2017, 146, 268-272.	0.6	5
669	Rationale and study protocol for the Patient-Centered Outcome Aid (PCOA) randomized controlled trial: A personalized decision tool for newly diagnosed ovarian cancer patients. <i>Contemporary Clinical Trials</i> , 2017, 57, 29-36.	0.8	3
670	A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 145, 236-242.	0.6	17
671	Ovarian Cancer and Resistance to Therapies: Clinical and Laboratory Perspectives. , 2017, , 511-537.		0
672	Drug Resistance in Bacteria, Fungi, Malaria, and Cancer. , 2017, , .		13
674	Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy. <i>Annals of Surgical Oncology</i> , 2017, 24, 3640-3646.	0.7	25
675	Utilization of intraperitoneal chemotherapy for optimally cytoreduced advanced stage epithelial ovarian cancer: A 10-year single institution experience with a racially diverse urban population. <i>Gynecologic Oncology</i> , 2017, 147, 36-40.	0.6	7
676	Contributions of the Japanese Gynecologic Oncology Group (JGOG) in Improving the Quality of Life in Women With Gynecological Malignancies. <i>Current Oncology Reports</i> , 2017, 19, 25.	1.8	3
677	Cytoreductive Surgery and HIPEC in the First-Line and Interval Time Points of Advanced Epithelial Ovarian Cancer. <i>Indian Journal of Gynecologic Oncology</i> , 2017, 15, 11-20.	0.1	6
678	Revised clinical pathway for the management of peritoneal metastases from colorectal cancer using NCCN 2017 guidelines. <i>Colorectal Cancer</i> , 2017, 6, 75-82.	0.8	2
679	Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer?. <i>Annals of Oncology</i> , 2017, 28, viii40-viii45.	0.6	43
680	Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer. <i>F1000Research</i> , 2017, 6, 84.	0.8	16
681	Normothermic intraperitoneal chemotherapy long term (NIPEC-LT) in the management of peritoneal surface malignancy, an overview. <i>Pleura and Peritoneum</i> , 2017, 2, 85-93.	0.5	9

#	ARTICLE	IF	CITATIONS
682	Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2539-2551.	1.0	45
683	Timing of Cytoreductive Surgery in the Treatment of Advanced Epithelial Ovarian Carcinoma. , 2017, , 59-78.		0
684	Novel Chemotherapy Tools. , 2017, , 171-180.		0
685	Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival of epithelial ovarian cancer: a systematic review and meta-analysis of observational studies. <i>Oncotarget</i> , 2017, 8, 46414-46424.	0.8	27
686	Long-Term Survival Analysis of Intraperitoneal versus Intravenous Chemotherapy for Primary Ovarian Cancer and Comparison between Carboplatin- and Cisplatin-based Intraperitoneal Chemotherapy. <i>Journal of Korean Medical Science</i> , 2017, 32, 2021.	1.1	12
687	Adjuvant chemotherapy with bevacizumab (i.p.) can prolong survival time of patients with advanced ovarian cancer after cytoreduction. <i>Neoplasma</i> , 2017, 64, 108-113.	0.7	1
688	Two protein-coding genes act as a novel clinical signature to predict prognosis in patients with ovarian serous cystadenocarcinoma. <i>Oncology Letters</i> , 2018, 15, 3669-3675.	0.8	7
690	Neoadjuvant chemotherapy or primary debulking surgery in FIGO IIIC and IV patients; results from a survey study in the Netherlands. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2018, 223, 98-102.	0.5	4
691	Intraperitoneal chemotherapy for ovarian cancer using sustained-release implantable devices. <i>Expert Opinion on Drug Delivery</i> , 2018, 15, 481-494.	2.4	24
692	Treatment of patients with peritoneal metastases from gastric cancer. <i>Annals of Gastroenterological Surgery</i> , 2018, 2, 116-123.	1.2	66
693	HIPEC Methodology, Comparison of Techniques, and Drug Regimens: Is There a Need for Standardization?. , 2018, , 79-102.		0
694	OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer. <i>Annals of Oncology</i> , 2018, 29, 431-438.	0.6	54
695	Timing is everything: intraperitoneal chemotherapy after primary or interval debulking surgery for advanced ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 55-63.	1.1	4
696	Treatment of Peritoneal Carcinomatosis. , 2018, , 245-262.		0
697	Cisplatin-induced gastrointestinal toxicity: An update on possible mechanisms and on available gastroprotective strategies. <i>European Journal of Pharmacology</i> , 2018, 827, 49-57.	1.7	120
698	Epithelial Ovarian Cancer. , 2018, , 253-289.e14.		3
699	Clinical studies in CRS and HIPEC: Trials, tribulations, and future directionsâ€”A systematic review. <i>Journal of Surgical Oncology</i> , 2018, 117, 245-259.	0.8	36
700	A new animal model for hyperthermic intraperitoneal chemotherapy (HIPEC) in tumor-bearing mice in the treatment of peritoneal carcinomatosis of ovarian origin. <i>Journal of Visceral Surgery</i> , 2018, 155, 183-189.	0.4	11

#	ARTICLE	IF	CITATIONS
701	Impact of increased utilization of neoadjuvant chemotherapy on survival in patients with advanced ovarian cancer: experience from a comprehensive cancer center. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e63.	1.0	12
702	Reannotation and Analysis of Clinical and Chemotherapy Outcomes in the Ovarian Data Set From The Cancer Genome Atlas. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-16.	1.0	8
703	Treatment Tolerance and Side Effects of Intraperitoneal Carboplatin and Dose-Dense Intravenous Paclitaxel in Ovarian Cancer. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2018, 40, 1283-1287.e1.	0.3	10
704	Novel Surgical Strategies in the Treatment of Gynecological Malignancies. <i>Current Treatment Options in Oncology</i> , 2018, 19, 73.	1.3	12
705	Biological Activity of Resveratrol on an Ovarian Cancer Cell. , 2018, , 231-244.		0
706	Current First-line Therapy for Ovarian Cancer: A Comprehensive Review. <i>Obstetrical and Gynecological Survey</i> , 2018, 73, 650-657.	0.2	9
707	Diagnosis and Treatment of Ovarian Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 943-964.	0.9	185
708	Splenectomy during cytoreductive surgery in epithelial ovarian cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 3473-3482.	0.9	14
709	It's time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 151, 555-561.	0.6	29
710	Patients with BRCA mutations have superior outcomes after intraperitoneal chemotherapy in optimally resected high grade ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 151, 477-480.	0.6	26
711	Cancer of the ovary, fallopian tube, and peritoneum. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 143, 59-78.	1.0	205
712	Heated Intraperitoneal Chemotherapy in the Management of Advanced Ovarian Cancer. <i>Cancers</i> , 2018, 10, 296.	1.7	20
713	Clinical Management of Epithelial Ovarian Cancer. , 2018, , 135-151.		0
714	Clinical benefit of controversial first line systemic therapies for advanced stage ovarian cancer â€” ESMO-MCBS scores. <i>Cancer Treatment Reviews</i> , 2018, 69, 233-242.	3.4	9
716	Personalising Treatment for High-Grade Serous Ovarian Carcinoma. <i>Clinical Oncology</i> , 2018, 30, 515-524.	0.6	16
717	Metastatic gynecologic malignancies: advances in treatment and management. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 521-533.	1.7	11
718	Prognostic significance of preoperative serum albumin in epithelial ovarian cancer patients: a systematic review and dose–response meta-analysis of observational studies. <i>Cancer Management and Research</i> , 2018, Volume 10, 815-825.	0.9	21
720	Intraperitoneal Chemotherapy: Historic Anomaly or Hope for the Future?. <i>Clinical Oncology</i> , 2018, 30, 484-492.	0.6	1

#	ARTICLE	IF	CITATIONS
722	Primary tumor and pre-metastatic niches co-targeting peptide-organic hybrid hydroxyapatite nanoparticles for metastatic breast cancer treatment. <i>Biomaterials Science</i> , 2018, 6, 2591-2604.	2.6	36
723	Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591878850.	1.4	4
724	The Clearance of Serum Human Epididymis Protein 4 Following Primary Cytoreductive Surgery for Ovarian Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1066-1072.	1.2	2
725	Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial. <i>British Journal of Cancer</i> , 2018, 119, 12-18.	2.9	9
726	Cytoreductive Surgery and Intraperitoneal Chemotherapy for Advanced Epithelial Ovarian Cancer. , 2018, , 221-252.		0
727	Surgical Management of Recurrent Epithelial Ovarian Cancer. , 2018, , 253-280.		1
728	Early Postoperative Intraperitoneal Chemotherapy: Current Role and Future Perspectives. , 2018, , 103-133.		1
729	Utilization of an Alternative Docetaxel-based Intraperitoneal Chemotherapy Regimen in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 12-16.	0.6	3
730	Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study. <i>British Journal of Cancer</i> , 2019, 121, 425-428.	2.9	10
731	Is There a Role for Intraperitoneal Chemotherapy, Including HIPEC, in the Management of Ovarian Cancer?. <i>Journal of Clinical Oncology</i> , 2019, 37, 2420-2423.	0.8	23
732	Role of Intraperitoneal Therapy in the Initial Management of Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2416-2419.	0.8	17
733	Evolving Concepts in the Management of Newly Diagnosed Epithelial Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2386-2397.	0.8	16
735	Chemotherapy Resistance in Advanced Ovarian Cancer Patients. <i>Biomarkers in Cancer</i> , 2019, 11, 1179299X1986081.	3.6	185
736	Evaluation of a Simple and Safe Tumor Drilling Technique to Potentiate the Effect of Intraperitoneal Chemotherapy in the Treatment of Recurrent Epithelial Ovarian, Tubal, and Peritoneal Cancer: A Matched Retrospective Cohort Study. <i>Cancer Control</i> , 2019, 26, 107327481986377.	0.7	2
737	Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. <i>Lancet Oncology</i> , The, 2019, 20, e368-e377.	5.1	206
738	Preclinical evaluation of local prolonged release of paclitaxel from gelatin microspheres for the prevention of recurrence of peritoneal carcinomatosis in advanced ovarian cancer. <i>Scientific Reports</i> , 2019, 9, 14881.	1.6	25
739	Hopes and failures in front-line ovarian cancer therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 143, 14-19.	2.0	51
740	Current strategies for different paclitaxel-loaded Nano-delivery Systems towards therapeutic applications for ovarian carcinoma: A review article. <i>Journal of Controlled Release</i> , 2019, 311-312, 125-137.	4.8	64

#	ARTICLE	IF	CITATIONS
741	Treatment of Ovarian Cancer With Intraperitoneal Platinum: Heating Up the Debate. <i>Journal of Clinical Oncology</i> , 2019, 37, 3169-3170.	0.8	1
742	Role of intraperitoneal chemotherapy in ovarian cancer in the platinum-taxane-based era: A meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 136, 64-69.	2.0	15
743	Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma. <i>Obstetrics and Gynecology</i> , 2019, 133, 245-254.	1.2	38
744	Activation of LXR ² inhibits proliferation, promotes apoptosis, and increases chemosensitivity of gastric cancer cells by upregulating the expression of ATF4. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 14336-14347.	1.2	5
745	Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients. <i>Gynecologic Oncology</i> , 2019, 154, 420-425.	0.6	21
746	Model-based analysis of treatment effects of paclitaxel microspheres in a microscopic peritoneal carcinomatosis model in mice. <i>Pharmaceutical Research</i> , 2019, 36, 127.	1.7	12
747	Intraperitoneal (IP) port cytology after completion of primary therapy for advanced stage ovarian cancer: A novel approach to a "second look". <i>Gynecologic Oncology</i> , 2019, 154, 290-293.	0.6	2
748	The Evolving Landscape of Chemotherapy in Newly Diagnosed Advanced Epithelial Ovarian Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e141-e151.	1.8	14
749	Epithelial ovarian cancer: Evolution of management in the era of precision medicine. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 280-304.	157.7	821
750	Advanced Epithelial Ovarian Cancer: Do More Options Mean Greater Benefits?. <i>Journal of Clinical Oncology</i> , 2019, 37, 1359-1364.	0.8	7
751	ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. <i>Annals of Oncology</i> , 2019, 30, 672-705.	0.6	665
752	ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 728-760.	1.2	167
753	High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints. <i>International Journal of Molecular Sciences</i> , 2019, 20, 952.	1.8	381
754	Epithelial ovarian cancer. <i>Lancet, The</i> , 2019, 393, 1240-1253.	6.3	1,039
755	Shaping the standard of care in ovarian cancer management: A review of Gynecologic Oncology Group (GOG)/NRG oncology clinical trials of the past twenty years. <i>Gynecologic Oncology</i> , 2019, 153, 479-486.	0.6	6
756	Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations. <i>Cancers</i> , 2019, 11, 416.	1.7	49
757	Gynecological Cancers—the Changing Paradigm. <i>Indian Journal of Surgical Oncology</i> , 2019, 10, 156-161.	0.3	0
758	The use of cisplatin plus doxorubicin or paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) for stage IIIC or IV epithelial ovarian cancer: a comparative study. <i>Clinical and Translational Oncology</i> , 2019, 21, 1357-1363.	1.2	9

#	ARTICLE	IF	CITATIONS
759	Efficacy and safety of TC dose-dense chemotherapy as first-line treatment of epithelial ovarian cancer: a single-institution retrospective cohort study. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 347-353.	0.6	2
760	Low rate of intraperitoneal port placement in ovarian cancer patients, a population-based assessment. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1177-1181.	1.2	1
761	Phase I study of intravenous oxaliplatin and intraperitoneal docetaxel in recurrent ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 147-152.	1.2	4
763	Weekly Dose-Dense Paclitaxel and Triweekly Low-Dose Cisplatin: A Well-Tolerated and Effective Chemotherapeutic Regimen for First-Line Treatment of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 4794.	1.2	23
764	Validation of a peritoneal surface disease severity score in stage IIIC-IV ovarian cancer treated with cytoreduction and hyperthermic intraperitoneal chemotherapy. <i>Surgical Oncology</i> , 2019, 28, 57-61.	0.8	6
765	A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 589-598.	1.1	16
767	Effect of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Quality of Life in Patients with Peritoneal Mesothelioma. <i>Annals of Surgical Oncology</i> , 2020, 27, 117-123.	0.7	12
768	A retrospective study comparing the efficacy of dose-dense chemotherapy, intraperitoneal chemotherapy and dose-dense chemotherapy with hyperthermic intraperitoneal chemotherapy in the treatment of advanced stage ovarian carcinoma. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 244, 101-105.	0.5	11
769	Myricetin Abrogates Cisplatin-Induced Oxidative Stress, Inflammatory Response, and Goblet Cell Disintegration in Colon of Wistar Rats. <i>Plants</i> , 2020, 9, 28.	1.6	34
770	Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States. <i>Gynecologic Oncology</i> , 2020, 159, 681-686.	0.6	23
771	HIPEC plus EPIC paclitaxel for maximal perioperative treatments of advanced epithelial ovarian cancer. Long-term results of a pilot study. <i>Surgical Oncology</i> , 2020, 35, 441-446.	0.8	4
772	Treatment of epithelial ovarian cancer. <i>BMJ, The</i> , 2020, 371, m3773.	3.0	359
773	Evaluation of Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer. <i>JAMA Network Open</i> , 2020, 3, e2013940.	2.8	53
774	Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer. <i>Medicine (United States)</i> , 2020, 99, e22100.	0.4	2
775	Survival and recurrence after intraperitoneal chemotherapy use: Retrospective review of ovarian cancer hospital registry data. <i>Cancer Medicine</i> , 2020, 9, 7388-7397.	1.3	5
776	Enhancing Delivery of Small Molecule and Cell Based Therapies for Ovarian Cancer Using Advanced Delivery Strategies. <i>Advanced Therapeutics</i> , 2020, 3, 2000144.	1.6	1
777	Oncologic outcomes and morbidity following heated intraperitoneal chemotherapy at cytoreductive surgery for primary epithelial ovarian cancer: A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2020, 158, 218-228.	0.6	12
778	An overview and update of hyperthermic intraperitoneal chemotherapy in ovarian cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1479-1492.	0.9	8

#	ARTICLE	IF	CITATIONS
779	Tuning the Physicochemical Characteristics of Particle-Based Carriers for Intraperitoneal Local Chemotherapy. <i>Pharmaceutical Research</i> , 2020, 37, 119.	1.7	8
780	Does timing of intraperitoneal chemotherapy initiation following primary cytoreductive surgery with bowel resection impact outcomes in patients with advanced ovarian cancer?. <i>Gynecologic Oncology</i> , 2020, 158, 622-630.	0.6	2
781	Intraperitoneal chemotherapy for peritoneal metastases: an expert opinion. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 511-522.	2.4	29
782	Unusually favorable outcome of 6 consecutive patients with diffuse malignant peritoneal mesothelioma treated with repeated doses of intraperitoneal paclitaxel. A case series. <i>Surgical Oncology</i> , 2020, 33, 96-99.	0.8	10
783	Boosting Replication and Penetration of Oncolytic Adenovirus by Paclitaxel Eradicate Peritoneal Metastasis of Gastric Cancer. <i>Molecular Therapy - Oncolytics</i> , 2020, 18, 262-271.	2.0	21
784	Bidirectional treatment of peritoneal metastasis with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) and systemic chemotherapy: a systematic review. <i>BMC Cancer</i> , 2020, 20, 105.	1.1	29
785	Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 156, 530-534.	0.6	6
786	Tuning Nanoparticle Interactions with Ovarian Cancer through Layer-by-Layer Modification of Surface Chemistry. <i>ACS Nano</i> , 2020, 14, 2224-2237.	7.3	64
787	Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. <i>Diagnostics</i> , 2020, 10, 43.	1.3	23
788	Intraperitoneal paclitaxel and cisplatin compared with dose-dense paclitaxel and carboplatin for patients with stage III ovarian cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1566-1574.	0.5	3
789	Aberrant sialylation in ovarian cancers. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 337-344.	0.6	42
790	Comparing Paclitaxel+Carboplatin with Paclitaxel+Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIc Serous-Type Tubo-Ovarian Cancer. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 2213.	1.2	33
791	The Evolving Management of Peritoneal Surface Malignancies. <i>Current Problems in Surgery</i> , 2021, 58, 100860.	0.6	2
792	Prognostic factors associated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 152, 202-207.	1.0	5
793	Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Oxaliplatin as Induction Therapy for Patients with Advanced Gastric Cancer with Peritoneal Metastases. <i>Annals of Surgical Oncology</i> , 2021, 28, 3863-3870.	0.7	19
794	HIPEC after neoadjuvant chemotherapy and interval debulking is associated with development of platinum-refractory or -resistant disease. <i>Gynecologic Oncology</i> , 2021, 161, 25-33.	0.6	8
795	The impacts of neoadjuvant chemotherapy and of cytoreductive surgery on 10-year survival from advanced ovarian cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 153, 417-423.	1.0	9
796	Novel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectable Peritoneal Metastases from High-Grade Appendiceal Ex-Goblet Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 1777-1785.	0.7	4

#	ARTICLE	IF	CITATIONS
798	Application of IPC, HIPEC, and PIPAC. , 2021, , 111-133.		0
799	The Role of HIPEC in the Treatment of Ovarian Cancer. , 2021, , 209-216.		0
800	Epithelial Ovarian Cancer. , 2021, , 633-641.		0
801	History of intraperitoneal platinum drug delivery for ovarian cancer and its future applications. , 2021, 4, 453-462.		2
802	Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 191-226.	2.3	356
803	Systemic treatment of newly diagnosed advanced epithelial ovarian cancer: From chemotherapy to precision medicine. Critical Reviews in Oncology/Hematology, 2021, 158, 103209.	2.0	11
804	Disease Distribution at Presentation Impacts Benefit of IP Chemotherapy Among Patients with Advanced-Stage Ovarian Cancer. Annals of Surgical Oncology, 2021, 28, 6705-6713.	0.7	1
805	Ovarian Carcinoma with Peritoneal Metastasis: Rethinking of Management. Archives of Clinical and Experimental Medicine, 2021, 6, 32-36.	0.1	0
807	Intraperitoneal paclitaxel: pharmacology, clinical results and future prospects. Journal of Gastrointestinal Oncology, 2021, 12, S231-S239.	0.6	16
808	Narrative review of cytoreductive surgery and intraperitoneal chemotherapy for peritoneal metastases in ovarian cancer. Journal of Gastrointestinal Oncology, 2021, 12, S137-S143.	0.6	4
809	Comparison of dose-dense vs. 3-weekly paclitaxel and carboplatin in the first-line treatment of ovarian cancer in a propensity score-matched cohort. BMC Cancer, 2021, 21, 525.	1.1	3
810	Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Gynecologic Oncology, 2021, 161, 389-395.	0.6	11
811	Dense hyperthermic intraperitoneal chemotherapy with cisplatin in patients with stage III serous epithelial ovarian cancer: a retrospective study. BMC Cancer, 2021, 21, 738.	1.1	8
812	Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results. Cancers, 2021, 13, 3196.	1.7	3
813	HIPEC Methodology and Regimens: The Need for an Expert Consensus. Annals of Surgical Oncology, 2021, 28, 9098-9113.	0.7	22
814	Acute renal disease in patients with ovarian peritoneal carcinomatosis treated with cytoreduction and HIPEC: the influence of surgery and the cytostatic agent used. Langenbeck's Archives of Surgery, 2021, 406, 2449-2456.	0.8	1
815	Efficacy and toxicity of intraperitoneal chemotherapy as compared to intravenous chemotherapy in the treatment of patients with advanced ovarian cancer. International Journal of Gynecology and Obstetrics, 2021, , .	1.0	3
816	A CLEARER VIEW ON OVARIAN CLEAR CELL CARCINOMA. Acta Clinica Belgica, 2021, , 1-13.	0.5	4

#	ARTICLE	IF	CITATIONS
817	Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study. <i>Gynecologic Oncology</i> , 2021, 163, 392-397.	0.6	0
818	A Modified Intraperitoneal Chemotherapy Regimen for Ovarian Cancer: Technique and Treatment Outcomes. <i>Cancers</i> , 2021, 13, 4886.	1.7	0
819	Systemic Therapy for Gynecologic Malignancies. , 2021, , 155-159.		0
820	Delivery of Nanoconstructs in Cancer Therapy: Challenges and Therapeutic Opportunities. <i>Advanced Therapeutics</i> , 2021, 4, 2000206.	1.6	18
821	Aszites und intraperitoneale Chemotherapie. , 2006, , 1061-1068.		1
822	Current Status of Intraperitoneal Antineoplastic Drug Delivery. , 2007, 134, 153-169.		3
823	Biomarker Targets and Novel Therapeutics. <i>Cancer Treatment and Research</i> , 2009, 149, 85-105.	0.2	3
824	Systemic Therapy for Ovarian Cancer, Current Treatment, Recent Advances, and Unmet Needs. , 2011, , 1-33.		4
827	Ovaries and Fallopian Tubes. , 2008, , 1827-1855.		2
828	Epithelial Ovarian Cancer. , 2007, , 313-367.		7
829	Cancer of the Ovary. , 2010, , 1052-1066.		1
831	DNA-binding agents. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2003, 21, 171-209.	0.5	5
832	DNA-binding agents. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2005, , 163-203.	0.5	5
833	Systemic therapy for gynecological neoplasms: Ovary, cervix, and endometrium. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2005, , 515-544.	0.5	11
834	Survival After Second-Line Intraperitoneal Therapy for the Treatment of Epithelial Ovarian Cancer: The Gynecologic Oncology Group Experience. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 223-229.	1.2	11
835	Outpatient Platinum-Taxane Intraperitoneal Chemotherapy Regimen for Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 1195-1198.	1.2	9
836	Trials With Impact on Clinical Management: First Line. <i>International Journal of Gynecological Cancer</i> , 2009, 19, S55-S62.	1.2	18
837	Intraperitoneal Chemotherapy: Why the Fuzz?. <i>International Journal of Gynecological Cancer</i> , 2010, 20, S14-S16.	1.2	2

#	ARTICLE	IF	CITATIONS
838	Intraperitoneal Treatment in Ovarian Cancer: The Gynecologic Oncology Group Perspective in 2012. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 345-348.	1.8	4
839	Preclinical activity of melflufen (J1) in ovarian cancer. <i>Oncotarget</i> , 2016, 7, 59322-59335.	0.8	13
840	Protein-coding genes, long non-coding RNAs combined with microRNAs as a novel clinical multi-dimension transcriptome signature to predict prognosis in ovarian cancer. <i>Oncotarget</i> , 2017, 8, 72847-72859.	0.8	11
841	Incidence and predictors of peritoneal metastases of gynecological origin: a population-based study in the Netherlands. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e58.	1.0	31
842	Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancers: is there a role?. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 10-7.	0.6	5
843	Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 45-57.	0.6	80
844	Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review-past, present and future. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 143-57.	0.6	37
845	Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomes. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 129-42.	0.6	17
846	Intraperitoneal Chemotherapy as a Multimodal Treatment for Gastric Cancer Patients with Peritoneal Metastasis. <i>Journal of Cancer Therapy</i> , 2013, 04, 6-15.	0.1	7
847	Safety and efficacy of pemetrexed in gynecologic cancers: A systematic literature review. <i>Modern Chemotherapy</i> , 2013, 02, 19-32.	0.5	6
848	Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2010, 2, 19.	0.8	48
849	Rationale and techniques of cytoreductive surgery and peritoneal chemohyperthermia. <i>World Journal of Gastrointestinal Oncology</i> , 2011, 3, 169.	0.8	18
850	Breakthrough therapy for peritoneal carcinomatosis of gastric cancer: Intraperitoneal chemotherapy with taxanes. <i>World Journal of Gastrointestinal Oncology</i> , 2015, 7, 285.	0.8	29
851	Salvage intraperitoneal chemotherapy for relapsed type II endometrial cancer: A pilot case-control study. <i>Journal of the Turkish German Gynecology Association</i> , 2016, 17, 176-181.	0.2	3
852	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in epithelial ovarian cancer: State of the art. <i>World Journal of Obstetrics and Gynecology</i> , 2013, 2, 94.	0.5	5
853	NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 896-909.	2.3	200
854	Intra-Peritoneal Cisplatin Combined with Intravenous Paclitaxel in Optimally Debulked Stage 3 Ovarian Cancer Patients: An Izmir Oncology Group Study. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 6165-6169.	0.5	1
855	Investigating Preoperative Hematologic Markers for Prediction of Ovarian Cancer Surgical Outcome. <i>Asian Pacific Journal of Cancer Prevention</i> , 2016, 17, 1445-1448.	0.5	18

#	ARTICLE	IF	CITATIONS
856	Chemotherapy of ovarian cancer in elderly patients. <i>Cancer Biology and Medicine</i> , 2015, 12, 292-301.	1.4	10
857	An Introduction to the Current Management of Ovarian Cancer in the Era of Precision Oncology. , 2021, , 19-57.		0
858	Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e95.	1.0	5
859	Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 155, 61-85.	1.0	145
860	Ovarialkarzinom. , 2002, , 663-675.		0
861	Systemic therapy for gynecological neoplasms: ovary, cervix and endometrium. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2003, 21, 565-584.	0.5	4
864	Primary Chemotherapy for Advanced Epithelial Ovarian Cancer. , 2004, , 429-445.		0
865	A Systematic Review and Meta-Analysis of Randomized Trials. , 2007, , 31-44.		11
866	Neoplastic Diseases of the Ovary. , 2007, , 839-881.		4
867	Intraperitoneal Chemotherapy in the Management of Ovarian Cancer. , 2007, , 165-176.		0
868	Management of Peritoneal Surface Malignancy: A Short History. , 2007, 169, 1-9.		2
869	Adjuvant Intraperitoneal Chemotherapy: A Review. , 2007, 169, 83-89.		3
870	Update in Oncology. <i>Annals of Internal Medicine</i> , 2007, 147, 775.	2.0	0
871	Intraperitoneal Chemotherapy: An Important Strategy in Ovarian Cancer Treatment. , 2009, , 329-333.		0
872	Platinum Compounds: Key Ingredients in Ovarian Cancer Treatment and Strategies. , 2009, , 317-328.		0
873	Intraperitoneal Chemotherapy: Phase III Trials. , 2010, , 37-50.		0
874	Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy: An Ongoing Research Effort. , 2010, , 109-127.		0
875	Criteria for Using Intraperitoneal (IP) Chemotherapy for Advanced Ovarian Cancer. , 2010, , 51-58.		0

#	ARTICLE	IF	CITATIONS
877	Epidemiology and Clinical Presentation of Ovarian Cancer. , 2010, , 1-15.		0
878	Chemotherapy for Ovarian Cancer. , 2010, , 143-161.		0
879	Principles of Intraperitoneal Chemotherapy. , 2010, , 27-35.		0
881	Current Chemotherapy of Ovarian Cancer. , 2010, , 7-25.		0
882	Ovarialkarzinom: alte Probleme und neue L�sungsans�tze. , 2011, , 425-451.		0
883	Intraperitoneale Chemotherapie in der Behandlung des Ovarial- und Tubenkarzinoms. , 2011, , 125-131.		0
885	Ovarian Cancer Chemotherapy. , 2011, , 2676-2680.		0
886	Surface Epithelial Tumors: Clinical Introduction. , 2011, , 47-53.		1
888	CHEMOTHERAPY IN GYNECOLOGIC MALIGNANCIES. , 2011, , 1-36.		0
890	Peripheral Neuropathy in Ovarian Cancer. , 0, , .		0
892	Ovarian Cancer: Primary Chemotherapy. , 2013, , 171-181.		0
893	Pharmacology of cancer chemotherapy drugs for hyperthermic intraperitoneal peroperative chemotherapy in epithelial ovarian cancer. World Journal of Obstetrics and Gynecology, 2013, 2, 143.	0.5	1
894	Neoplastic Diseases of the Ovary. , 2013, , 731-771.		1
895	Fatigue, mood, and sleep, during intraperitoneal chemotherapy: a pilot case control study. International Journal of Psychological Research, 2013, 6, 8-14.	0.3	3
897	Quality of Life in Patients with Ovarian Cancer. , 2014, , 241-260.		2
898	Ovarium- en tubacarcinoom. , 2014, , 159-167.		0
899	Metronomic Chemotherapy in Gynecological Cancers. , 2014, , 203-216.		0
900	Cancers Arising in the Ovary. , 2014, , 1592-1613.e6.		1

#	ARTICLE	IF	CITATIONS
901	Cancer of Ovary (Epithelial Ovarian Cancer). , 2014, , 349-436.		0
902	Epithelial Ovarian Cancer, Low Malignant Potential, and Sex Cord Stromal Tumors of the Ovary. , 2015, , 3-53.		1
904	Tumorerkrankungen in der GynÄkologie â€œ Ovarialkarzinom. , 2015, , 1-7.		0
905	Extended Surgery for Advanced Ovarian Cancer. , 2015, , 429-440.		0
907	Specific features of current intraperitoneal therapy in patients with ovarian cancer. Opuholi Zenskoj Reproktivnoy Sistem, 2016, 12, 85-93.	0.1	2
908	Epithelial Ovarian Cancers: On-Target is Better than Near-Target. Chemotherapy, 2016, 05, .	0.0	0
909	Ovarian Cancer Chemotherapy. , 2017, , 3268-3272.		0
910	Management of Ovarian Cancer in the Elderly Population. Comprehensive Gynecology and Obstetrics, 2017, , 281-303.	0.0	0
911	The role of hyperthermic intraperitoneal chemotherapy in the treatment of advanced and recurrent ovarian cancer. Onkologie (Czech Republic), 2017, 11, 220-223.	0.0	0
912	Indikation von CRS und HIPEC bei peritonealen Metastasen von Ovarialkarzinomen. , 2018, , 213-221.		0
913	Applikation von IPC, HIPEC und PIPAC. , 2018, , 119-141.		0
914	Ovarian Cancer in the Older Woman. , 2018, , 1-12.		0
915	Over kanserinde intraperitoneal kemoterapi esnasÄ±nda geliÅŸen katater iliÅŸkili komplikasyonlarÄ±n yÄ¶netimi: Å°ki olgu sunumu ve literatÄ¼r derlemesi. Marmara Medical Journal, 2018, 31, 88-93.	0.2	2
916	Intraperitoneale Chemotherapie in der Behandlung des Ovarial- und Tubenkarzinoms. , 2019, , 131-140.		0
917	Palliative Chirurgie des Ovarialkarzinoms. , 2019, , 311-323.		0
918	Long-term survival after intraperitoneal chemotherapy with paclitaxel-cisplatin for recurrent primary peritoneal cancer resistant to multiple lines of intravenous chemotherapy. Obstetrics and Gynecology Science, 2019, 62, 285.	0.6	1
919	Gynecologic Cancers: Ovarian Cancer. , 2019, , .		0
920	Historical Perspective for Regional Peritoneal Therapy: HIPEC, EPIC, and Port-Based Therapy. , 2020, , 75-81.		0

#	ARTICLE	IF	CITATIONS
921	Regional Therapy for the Treatment of Ovarian Cancer: HIPEC and Intraperitoneal Chemotherapy. , 2020, , 125-140.		0
922	Peritoneal Perfusion Techniques. , 2020, , 199-211.		1
923	Comparisons of Clinical Outcomes in Women with Advanced Ovarian Cancer Treated with Frontline Intraperitoneal versus Dose-Dense Platinum/Paclitaxel Chemotherapy without Bevacizumab. International Journal of Environmental Research and Public Health, 2020, 17, 3603.	1.2	2
924	Prognostic Significance of CA125 Dynamic Change for Progression Free Survival in Patients with Epithelial Ovarian Carcinoma. Medical Science Monitor, 2020, 26, e925051.	0.5	2
925	Ovarian Cancer in the Older Woman. , 2020, , 773-784.		0
926	Intraperitoneale Chemotherapie in der Behandlung des Ovarial- und Tubenkarzinoms. , 2014, , 135-142.		0
927	Intraperitoneal chemotherapy for the treatment of ovarian cancer. Women's Oncology Review, 2005, 5, 203-211.	0.0	0
934	Regional Therapy in Ovarian Cancer. , 2007, , 329-341.		0
935	Targeted Therapy in Epithelial Ovarian Cancer. , 2008, , 261-269.		0
936	Ovarialkarzinom. , 2008, , 421-430.		0
937	Current management of ovarian carcinoma. Therapy: Open Access in Clinical Medicine, 2005, 2, 275-286.	0.2	0
938	Maligne Ovarialtumoren. , 0, , 1184-1244.		0
939	Locoregional Chemotherapy Including Perfusion. , 2008, , 33-46.		0
940	Ovarian and Fallopian Tube Cancers. Medical Radiology, 2008, , 331-342.	0.0	1
941	Intraperitoneale (i.p.) Chemotherapie in der Behandlung des Ovarial- und Tubenkarzinoms. , 2009, , 125-131.		0
943	CHFR and Paclitaxel Sensitivity of Ovarian Cancer. Cancers, 2021, 13, 6043.	1.7	0
944	Cytoreductive Surgery With or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer: A Phase 3 Clinical Trial. Annals of Surgical Oncology, 2022, 29, 2617-2625.	0.7	49
946	I.p.-injected cationic liposomes are retained and accumulate in peritoneally disseminated tumors. Journal of Controlled Release, 2022, 341, 524-532.	4.8	4

#	ARTICLE	IF	CITATIONS
947	Cytoreductive Surgery and Intraperitoneal Chemotherapy in Advanced Serous Epithelial Ovarian Cancer: A 14-Year French Retrospective Single-Center Study of 124 Patients. <i>Annals of Surgical Oncology</i> , 2022, 29, 3322-3334.	0.7	3
948	Modified Intraperitoneal Chemotherapy Without Bevacizumab as a First-Line Therapy for Newly Diagnosed Advanced Epithelial Ovarian Cancer-Two Centers Experiences. <i>Frontiers in Medicine</i> , 2022, 9, 846352.	1.2	2
949	Optimizing regional chemotherapy for epithelial ovarian cancer. <i>Journal of Obstetrics and Gynaecology Research</i> , 2022, , .	0.6	2
950	Plasma-activated medium inhibits cancer stem cell-like properties and exhibits a synergistic effect in combination with cisplatin in ovarian cancer. <i>Free Radical Biology and Medicine</i> , 2022, 182, 276-288.	1.3	8
951	Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer. <i>Biomedicines</i> , 2022, 10, 77.	1.4	12
952	OUP accepted manuscript. <i>Japanese Journal of Clinical Oncology</i> , 2022, , .	0.6	0
953	Consolidation therapy for ovarian cancer. <i>Women's Oncology Review</i> , 2005, 5, 3-8.	0.0	0
954	Locoregional Chemotherapy Including Perfusion. , 2008, , 33-46.		0
955	Intraperitoneal Chemotherapy for Ovarian Cancer. , 2008, 622, 145-151.		0
957	Modulation of p53 expression in cancer-associated fibroblasts prevents peritoneal metastasis of gastric cancer. <i>Molecular Therapy - Oncolytics</i> , 2022, 25, 249-261.	2.0	7
958	What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (â‰¥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer. <i>Gynecologic Oncology</i> , 2022, 166, 410-416.	0.6	4
959	Transmembrane Phosphatase with TEnsin Homologue (TPTE) Expression in Epithelial Ovarian Cancer. <i>Annals of Health Research</i> , 2022, 8, 121-130.	0.1	0
960	NIPEC with Single-Dose Intraperitoneal Cisplatin and Paclitaxel in Stage III Epithelial Ovarian Cancer. <i>South Asian Journal of Cancer</i> , 0, , .	0.2	0
961	The contemporary management of peritoneal metastasis: A journey from the cold past of treatment futility to a warm present and a bright future. <i>Ca-A Cancer Journal for Clinicians</i> , 2023, 73, 49-71.	157.7	23
962	Electrical based cancer therapy for solid tumours - Theranostics approach. <i>Biosensors and Bioelectronics: X</i> , 2022, 11, 100214.	0.9	1
963	Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials. <i>ESMO Open</i> , 2022, 7, 100586.	2.0	20
964	Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382211045.	0.8	3
965	Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	12

#	ARTICLE	IF	CITATIONS
966	Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial. <i>Clinical Cancer Research</i> , 2023, 29, 349-363.	3.2	7
967	Management of Epithelial Ovarian Cancer with Peritoneal Metastases. , 2022, , 171-177.		0
969	Epithelial ovarian cancer. , 2023, , 250-281.e8.		0
970	Survival Outcomes of Epithelial Ovarian Cancer Patients Following Dose-dense Versus 3-Weekly Platinum+Paclitaxel Chemotherapy: A Meta-Analysis. <i>Clinical Oncology</i> , 2022, , .	0.6	0
971	Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes. <i>Cancers</i> , 2022, 14, 6010.	1.7	4
972	Peritoneal-based Malignancies and Their Treatment. <i>Annals of the Academy of Medicine, Singapore</i> , 2010, 39, 54-57.	0.2	18
973	Nab-PIPAC: a phase IB study protocol of intraperitoneal cisplatin and nab-paclitaxel administered by pressurised intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of advanced malignancies confined to the peritoneal cavity. <i>BMJ Open</i> , 2023, 13, e067691.	0.8	2
974	Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 1: A Systematic Review and Network Meta-Analysis. <i>American Journal of Therapeutics</i> , 2023, 30, e36-e55.	0.5	4
975	Epithelial Ovarian Cancer. , 2022, , 291-323.		1
976	Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2023, 91, 247-256.	1.1	0
977	Nanotechnology-integrated ovarian cancer metastasis therapy: Insights from the metastatic mechanisms into administration routes and therapy strategies. <i>International Journal of Pharmaceutics</i> , 2023, 636, 122827.	2.6	3
979	Prognostic Value of En-Block Radical Bowel Resection in Advanced Ovarian Cancer Surgery With HIPEC. <i>Cancer Control</i> , 2023, 30, .	0.7	2
983	Heterogeneity and treatment landscape of ovarian carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 820-842.	12.5	3
988	Exploring the Intraperitoneal Route in a New Way for Preclinical Testing. , 2023, , 217-239.		0